



Review

# Targeting Homocysteine and Hydrogen Sulfide Balance as Future Therapeutics in Cancer Treatment

Avisek Majumder

Department of Medicine, University of California, San Francisco, CA 94143, USA; avisek.biochem@gmail.com

**Abstract:** A high level of homocysteine (Hcy) is associated with oxidative/ER stress, apoptosis, and impairment of angiogenesis, whereas hydrogen sulfide (H<sub>2</sub>S) has been found to reverse this condition. Recent studies have shown that cancer cells need to produce a high level of endogenous H<sub>2</sub>S to maintain cell proliferation, growth, viability, and migration. However, any novel mechanism that targets this balance of Hcy and H<sub>2</sub>S production has yet to be discovered or exploited. Cells require homocysteine metabolism via the methionine cycle for nucleotide synthesis, methylation, and reductive metabolism, and this pathway supports the high proliferative rate of cancer cells. Although the methionine cycle favors cancer cells for their survival and growth, this metabolism produces a massive amount of toxic Hcy that somehow cancer cells handle very well. Recently, research showed specific pathways important for balancing the antioxidative defense through H<sub>2</sub>S production in cancer cells. This review discusses the relationship between Hcy metabolism and the antiapoptotic, antioxidative, anti-inflammatory, and angiogenic effects of H<sub>2</sub>S in different cancer types. It also summarizes the historical understanding of targeting antioxidative defense systems, angiogenesis, and other protective mechanisms of cancer cells and the role of H<sub>2</sub>S production in the genesis, progression, and metastasis of cancer. This review defines a nexus of diet and precision medicine in targeting the delicate antioxidative system of cancer and explores possible future therapeutics that could exploit the Hcy and H<sub>2</sub>S balance.

**Keywords:** targeted therapy; cancer biology; hyperhomocysteinemia; gene–environment interaction; epigenetics; stress response



**Citation:** Majumder, A. Targeting Homocysteine and Hydrogen Sulfide Balance as Future Therapeutics in Cancer Treatment. *Antioxidants* **2023**, *12*, 1520. <https://doi.org/10.3390/antiox12081520>

Academic Editors: Wael El-Rifai and Isao Ishii

Received: 24 June 2023

Revised: 24 July 2023

Accepted: 28 July 2023

Published: 29 July 2023




**Copyright:** © 2023 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Cancer is the second leading cause of death after cardiovascular disease [1]. Current understanding characterizes cancer into six hallmarks: maintaining proliferative signaling, bypassing growth suppressors, resisting apoptosis, enabling replicative immortality, inducing angiogenesis, and initiating invasion and metastasis [2]. Due to the high proliferative rate, cancer cells depend on many nutrient sources from the diet [3]. Methionine is one of the nutrients that cancer cells require to maintain cell proliferation, growth, survival, and metastasis [4]. Methionine was the first amino acid used in protein synthesis in the eucaryotic system [5]. As an essential amino acid, methionine is not produced in our bodies, so it must be consumed from the diet [6]. Methionine is not only essential for the formation of all proteins, but it also provides lots of other metabolites that are required in multiple other metabolic processes [7]. Via the methionine cycle (Figure 1), methionine can be converted to S-Adenosyl methionine (SAM), the only methyl group donor in DNA, RNA, and histone methylation reactions. DNA, RNA, and histone methylation are dynamic; these regulate gene expression and alter cellular signaling [8]. After transferring methyl group, SAM converts to S-Adenosyl homocysteine (SAH), which then converts to homocysteine (Hcy) [7]. Hcy is a sulfur-containing nonproteinogenic amino acid; after production, half of the Hcy goes to the transsulfuration pathway to produce cysteine (a semi-essential amino acid), and another half of the Hcy can be remethylated back into methionine with the help of the folate cycle [7]. Cysteine is a semi-essential amino acid obtained from the diet

or by de novo synthesis from the methionine cycle [9]. In the transsulfuration pathway, when cysteine is produced, other than helping in protein formation, it is also used for hydrogen sulfide (H<sub>2</sub>S) and glutathione (GSH) production [7]. Due to the high proliferative rate, cancer cells mainly depend on the methionine cycle for methylation reaction as well as the production of H<sub>2</sub>S and GSH [10]. A study found that cancer cells express high levels of methionine transporter SLC43A2 for the consumption of more methionine, which causes cancer progression [11]. Many studies found that a methionine restriction diet can reduce cancer risk and progression through various molecular processes [10,12,13]. A phase 1 trial also showed that it is tolerable for metastatic cancer patients to be on a methionine-restricted diet to reduce tumor growth [14].



**Figure 1.** Schematic diagram of Hcy production through the methionine and folate cycle. (A) Dietary methionine is converted to homocysteine (Hcy) through S-adenosyl methionine (SAM) and S-adenosyl homocysteine (SAH) and then back to methionine (MET) via the remethylation pathway. Half of Hcy goes to the transsulfuration pathway, where it is converted to cysteine with the help of cystathionine- $\beta$  synthase (CBS) and cystathionine- $\gamma$  lyase (CSE). Then cysteine is further converted to glutathione (GSH); (B) Conversion of cobalamin (vitamin B12) to methyl-B12 in the presence of methionine synthase reductase (MTR) is necessary for remethylation of 5-methyl-tetrahydrofolate (THF) to THF; (C) Dietary folic acid (vitamin B9) enters the folate cycle after its conversion first to dihydrofolate (DHF) and then to THF. The 5, 10-methyltetrahydrofolate reductase (MTHFR) is a key enzyme that converts 5, 10-methylene-THF to 5-methyl-THF [15].


Cancer cells depend highly on the methionine cycle, producing a massive amount of Hcy [16]. As high levels of intracellular Hcy can be secreted to blood, so many studies correlate high Hcy levels with cancer [17–19]. More than 15  $\mu\text{mol/L}$  of Hcy in the blood is clinically termed hyperhomocysteinemia (HHcy) [7]. HHcy has been associated with multiple disease conditions, including cancer [20]. Elevated levels of Hcy are connected with oxidative stress, ER stress, apoptosis, protein oxidation, inflammation, and impaired angiogenesis [17,20]. Moreover, many previous studies found variable associations of polymorphisms of Hcy metabolism genes with cancer [21–23], suggesting the possible role of gene–environment interactions in the causation of cancer [24]. Some studies suggested that together with genetic polymorphisms, dietary methionine, folate, vitamin B12, B6, and alcohol consumption play an essential role in the genesis of tumors [25–27]. Also, different studies showed that specific genetic polymorphisms may induce risk for specific cancer types [28,29]. More studies are needed on a large number of patients in order to understand which genetic polymorphisms predispose to which types of cancer and how lifestyle modifications could be helpful in reducing cancer risk.

Cancer cells depend on the methionine cycle for their cellular turnover, producing toxic Hcy [20]. Cancer patients show high Hcy levels, but that does not mean that high Hcy is a risk factor for cancer, rather that cancer cells shuttle more Hcy to the transsulfuration pathway [20]. As high Hcy levels lead to many cellular pathogenesises, cancer cells transfer excess Hcy to the transsulfuration pathway for the production of H<sub>2</sub>S [20]. Recent studies revealed that cancer cells increased the expression of CBS (the rate-limiting enzyme in transsulfuration reaction) to reduce excess Hcy levels and produce H<sub>2</sub>S [30]. Previously, H<sub>2</sub>S was considered a toxic gas; however, recent research found that H<sub>2</sub>S has beneficial effects in reversing cellular pathophysiology [7]. H<sub>2</sub>S emerged as a third gasotransmitter after NO and CO [31], and it has been shown to have beneficial effects in reducing oxidative and ER stress, apoptosis, and inflammation, and improving neoangiogenesis [17]. Studies in colon and ovarian cancer mainly showed that this higher production of H<sub>2</sub>S induced tumor growth via inducing cell proliferation and angiogenesis [30]. Also, suppressing CBS expression led to a reduction in tumor growth [32]. This suggests that cancer cells maintain a balance of H<sub>2</sub>S and Hcy levels for their cellular growth and metastasis. Very limited studies have exploited this delicate balance of H<sub>2</sub>S and Hcy as a therapeutic opportunity for cancer treatment. Many studies showed that H<sub>2</sub>S reverses all the pathophysiological effects of Hcy [17]. Many antifolate drugs and drugs targeting Hcy metabolism have long been used to treat cancer; however, all showed limited clinical efficacy due to multiple reasons [19]. In the future, more research is needed that exploits the Hcy and H<sub>2</sub>S balance to treat cancer patients. This review article summarizes the Hcy metabolism and how Hcy metabolism and H<sub>2</sub>S production are associated with cancer. This review also discusses the current therapeutics and future therapeutic opportunities that target these pathways in cancer treatment.

## 2. Homocysteine Production and Hyperhomocysteinemia

As discussed in the above section, after production, half of the Hcy goes to the transsulfuration pathway, and the other half of the Hcy remethylates back to methionine with the help of the folate cycle [33–35]. As Hcy can be secreted into the blood, so different forms of Hcy can be found in blood circulation, as shown in Figure 2 [36]. In the transsulfuration pathway, Hcy is converted to cystathionine with the help of cystathionine β-synthase (CBS), where vitamin B6 (pyridoxine) is an essential co-factor [8]. This is the rate-limiting step of the transsulfuration pathway [8]. After production, cystathionine is further converted to cysteine by cystathionine γ-lyase (CSE), and this cysteine further produces GSH [37].

In normal conditions, cells maintain a delicate balance of Hcy production (through the methionine cycle) and elimination of Hcy (via the transsulfuration pathway) [37]. The normal range of plasma Hcy levels for young adults (~30 years) is 4.6–8.1 μM, and for older adults (30 years and above) is 4–15 μM [38]. In different disease conditions, the balance between the production and elimination of Hcy becomes affected [39,40]. High levels of Hcy in the blood circulation are called hyperhomocysteinemia (HHcy), a systemic disorder [7]. Patients with HHcy show more than 15 μM plasma Hcy [41]. HHcy has been classified as moderate (15–30 μM), intermediate (30–100 μM), and severe (>100 μM) [41]. Genetic mutations in the CBS and methylenetetrahydrofolate reductase (MTHFR) genes (involved in the folate cycle) can lead to HHcy [42–45]. Different genetic variants of the CBS and MTHFR genes that lead to HHcy can also be associated with other disease conditions (Table 1). Other than genetic factors, people also develop HHcy via various environmental factors, including consuming excess amounts of a methionine-rich diet, vitamin B12/folate deficiency, alcohol intake, diabetes, and the obstruction of renal clearance [46,47]. Under HHcy conditions, the methionine cycle is generally dysregulated [48], so this leads to the disruption of multiple signaling pathways because it is the only pathway that gives rise to the production of essential methyl groups needed for the subsequent biosynthesis of cellular compounds (for example, creatine, epinephrine, carnitine, phospholipids, proteins, and polyamines) and also methylation of DNA, RNA, and histones [8,49].



**Figure 2.** Different forms of homocysteine found in blood circulation: Hcy can be secreted from the cells and can be detected in blood in three different forms: around 1% as free thiol, 70–80% present bound with plasma proteins, and the remaining 20–30% present as homo/heterodimerized with other thiols.

**Table 1.** Association of Hyperhomocysteinemia with different disorders.

Genes	Polymorphisms	Condition	Associated Complications	References
CBS	844INS68	HHcy	Peripheral artery occlusive disease	[50]
	T833C	HHcy	Stroke	[51]
	844INS68	HHcy	Thrombosis	[52]
MTHFR	C677T	HHcy	Retinal vein occlusion	[53]
	C677T	HHcy	Stroke	[42–45]
	C677T	HHcy	Venous thromboembolism	[54]
	C677T	HHcy	Hypertension	[55–57]
	C677T	HHcy	Alzheimer's Disease	[58]
	A1298C	HHcy	Cerebral venous sinus thrombosis	[59–61]
	C677T	HHcy	Hyperlipidemia	[62]
	C677T	HHcy	Diabetic nephropathy	[63–66]
	C677T	HHcy	Cerebral venous thrombosis	[67]
	C677T	HHcy	Parkinson's Disease	[68,69]

### 3. Homocysteine Metabolism in Cancer

Hcy metabolism depends on several factors, including the intake of methionine in the diet, the production of SAM, and the type of cells in which methionine metabolism occurs [70]. Previous studies showed that high SAM levels can act as an allosteric inhibitor of methylenetetrahydrofolate reductase (MTHFR) [17]. MTHFR enzymes convert the 5,10-MTHF to 5-MTHF in the remethylation reaction [71]. So, high SAM levels prevent Hcy from entering the remethylation pathway. Interestingly a high SAM level also acts as an allosteric activator for the CBS, a rate-limiting enzyme of the transsulfuration pathway [72,73]. This

suggests that high SAM levels favor Hcy entering the transsulfuration pathway. Cancer cells depend on the methionine cycle for their methylation reaction, producing high SAM, which leads to more production of GSH and H<sub>2</sub>S via the transsulfuration pathway. Hcy metabolism also depends on the dietary methionine load, which can affect SAM synthesis, suggesting a link between diet and cancer risk [10,74–76]. Studies suggest that when our diet contains a basal methionine level, Hcy goes to the remethylation pathway about 1.5–2.0 times more than the transsulfuration pathway [77]. Alternatively, when we take high methionine levels from the diet, Hcy cycling through remethylation is reduced by about 1.5-fold [77]. HHcy is found in ~5–7% of the general population and is associated with other disorders [7], including cancer [8,78–81]. Hcy metabolism pathways, including the transsulfuration and remethylation pathways, are associated with several types of cancer [82–91]. Recent advancements in research found a close link between HHcy and cancer that is discussed in the following paragraph.

#### 4. Association of Hyperhomocysteinemia and Cancer

A study by Lily L Wu and James T Wu showed that patients (who were not taking antifolate drugs) with breast, ovarian and pancreatic carcinoma had elevated serum Hcy levels [92]. Elevated Hcy is also associated with a rapid proliferation rate of tumors in leukemia patients [93] and ovarian cancer [94]. Cancer cells have a high proliferation rate, so they depend more on the methionine cycle for the DNA, RNA, and histone methylation reactions. This methionine dependency or overproduction of Hcy could be a phenotypic expression of malignancy. This suggests that elevated Hcy could be an early carcinogenesis marker and a sensitive marker for detecting recurrence. Serum tumor markers have been used most frequently for monitoring cancer patients during therapy [95].

##### 4.1. High Plasma Hcy Levels and Cancer

High homocysteine levels have been associated with various types of cancer, as summarized in Table 2. These studies (in Table 2) suggest that patients with advanced-stage cancer show higher Hcy levels than patients with early-stage cancer. This suggests that high Hcy levels can lead to apoptosis, and cancer cells in the late stage are more proliferative, so they secrete Hcy outside the cells.

**Table 2.** Association of polymorphisms homocysteine metabolism genes with cancer risk. (odds ratio is indicated as OR).

Genes	Polymorphisms	Cancer Types	Significant Association (OR)	References	
MTHFR	677C->T	Breast Cancer	Positive Association (1.19)	[22]	
		Ovarian Cancer	No association (1.03)	[22]	
		Esophageal Squamous Cell Carcinoma	Positive Association (1.47)	[96]	
		Acute Lymphocytic Leukemia	Negative Association (0.99)	[21]	
		Prostate Cancer	Negative association (0.78)	[23]	
		Colorectal Adenomas	Negative association (0.76)	[97]	
		Late-stage colorectal tumorigenesis	Positive Association (1.32)	[29]	
		Endometrial Cancer	No association (1.10)	[98]	
		1298A->C	Prostate Cancer	Negative Association (0.58)	[99]
			Acute Lymphocytic Leukemia	Negative Association (0.33)	[21]
Acute Myeloid Leukemia	No association (1.00)		[88]		
Endometrial Cancer	No association (1.00)		[98]		

Table 2. Cont.

Genes	Polymorphisms	Cancer Types	Significant Association (OR)	References
MTRR	66A->G	Acute Myeloid Leukemia	Positive association for Asian population (1.40)	[100]
		Head and Neck Cancer	Positive Association (1.24)	[101]
		Colorectal Cancer	Positive Association (2.77, 1.15)	[87,102]
		Gastric Cancer	Positive Association (1.39)	[103]
		Breast Cancer	Positive Association (4.45)	[104]
MTR	b2756A->G	Colorectal Cancer	Positive Association (2.04)	[28]
		Primary Liver Cancer	No association (1.00)	[105]
		Breast Cancer	No association (1.00)	[106]
		Glioblastoma Multiforme	No association (1.00)	[107]
		Upper Gastrointestinal Tract cancer	No association (1.00)	[108]
MTHFD1	1958G->A	Gastric Cancer	Positive Association (2.05)	[110]
	G1958A	Colon Cancer	Negative Association (0.89)	[111]
BHMT	742G->A	Head and Neck Squamous Cell Carcinoma	Positive Association (1.34)	[112]
		Breast Cancer	No association (0.98)	[113]
		Cervical Cancer	Negative Association (0.433)	[114]
		Ovarian Cancer	No association (1.00)	[115]
TCN 2	776G->C	Colorectal Adenoma	Positive Association (1.09)	[116]
		Glioblastoma Multiforme	No association (1.00)	[107]
TYMS	TS 3'-UTR	Primary Central Nervous System Lymphoma	No association (1.00)	[117]
		Esophageal and Stomach Cancer	No association (1.00)	[118]

Additionally, patients who underwent surgery or chemotherapy showed increased Hcy levels in their blood. As most of the chemotherapy drugs (alkylating agents, antimetabolites, methotrexate, hormones, and antagonists) are antifolate, folate deficiency can increase Hcy levels in these patients [119]. Another study showed that older cancer patients have a higher risk of developing HHcy than younger [120], suggesting age is another causing factor for high Hcy levels in cancer patients. Venous thromboembolism (VTE) is the most common complication associated with cancer, and it is also shown to be the most common cause of death in cancer. Interestingly, HHcy patients also developed venous thromboembolism, suggesting a link between cancer-associated complications and high Hcy levels. Moreover, a study showed that cancer patients without HHcy did not show venous thromboembolism [121].

#### 4.2. Alteration in Hcy Metabolism Gene and Risk of Cancer

Previous studies have identified numerous enzyme mutations and polymorphisms (*MTHFR*, *CBS*, *MTRR*, *MTR*, *MTHFD*, *BHMT*, *TYMS*, *TCN 2*) that regulate Hcy metabolism [122–128]. These mutations and polymorphisms are often linked to HHcy and different cancer types (Table 2). The most common mutations in *MTHFR* 677C->T transition at codon 222 and 1298A->C transversion at codon 429 have been associated with cervical [68], colorectal [129], endometrial [130], and esophageal cancer [131]. Interestingly, the 677TT and 1298CC homozygotes have been found to have reduced prostate cancer risk, as the frequencies are very low (9 and 11%, respectively) [90,99], suggesting the risk factor of specific polymorphism

depends on the types of cancer. In addition to genetic polymorphisms, many environmental factors, including folate status, methionine, and the effects of alcohol consumption, play a vital role in the causation of cancer. This understanding gives rise to the targeted therapy approach, where specific mutation types can be targeted with a specific drug. Similarly, *MTRR* gene A66G Ile22Met is found to be associated with colorectal cancer [87] and leukemia [21]. It is also noted that homozygotes (GG) have a three-fold higher risk of colorectal cancer than with that heterozygote (AG) polymorphism. As this allelic frequency varies between the different ethnic groups, this suggests that some populations may have a higher risk for certain types than others. Likewise, one significant polymorphism (*MTR* A2756G; Asp919Gly) has been documented in *MTR* [28]. A 1958G->A; Ala653Gly polymorphism in the *MTHFD-1* gene was associated with acute lymphoid leukemia [132], but no association was reported with lung cancer [133]; an inverse association was reported with colon cancer.

#### 4.3. Homocysteine-Mediated Epigenetic Alterations and Risk of Cancer

Epigenetics are the process of changes in phenotype without alteration of the DNA sequence; this can be heritable or achieved through gene–environmental interaction [134]. There are three types of epigenetic modification: (1) DNA methylation, (2) histone modification, and (3) RNA interference. Methylation can occur in DNA, RNA, and histone protein, and this process is mediated via the methionine cycle. There are three DNA methyltransferase (DNMT) types: DNMT1, DNMT3a, and DNMT3b. SAMs act as a crucial substrate methylation reaction via DNMTs. SAM levels can be changed via environmental factors like a high methionine diet, folate deficiency, vitamin B6, and vitamin B12. Many studies have connected Global DNA hypomethylation to cancer [135], suggesting that cancer cells show differential signaling than normal cells due to high SAM levels.

Gene activation or deactivation depends upon the methylation pattern of the N-terminal tail of histones [136]. Moreover, crosstalk between these histone tail modifications (methylation, acetylation, and homocysteinylation) may have mechanistic linkages with different types of cancer [137]. Although many studies showed that high Hcy levels are associated with different epigenetic alterations and associated with cellular pathology [8,138], minimal studies have shown the role of these modifications in cancer. A study noted that Hcy in various concentrations might alter gene silencing and activation in different patterns [139]. Studies suggest that severe HHcy may induce more injurious effects via alteration of the methylation reaction [140].

Global genomic hypomethylation has been found in many types of cancer, including metastatic prostate, chronic lymphocytic, and hepatocellular carcinoma [141–144]. Regional hypomethylation of DNA sequences is also often observed during the early stages of tumorigenesis and in abnormal nonneoplastic tissue, such as hyperplasia [145]. DNA hypomethylation leads to the decondensation of pericentromeric heterochromatin and the activation of retrotransposon elements [146]; these have been associated with activating some oncogene and deactivating some tumor suppressor genes [147].

##### 4.3.1. Hcy-Mediated DNA Methylation and Cancer

A previous study showed that methionine-rich food induces intra-cellular SAM levels, and as a consequence, global hypermethylation occurs and induces Hcy levels [148]. Where another study noted elevated Hcy-induced SAH levels, this induced SAH, in turn, inhibited SAM-dependent methyltransferases (such as DNMTs) via a negative feedback mechanism [140]. These studies suggest high Hcy levels may result in DNA hyper/hypomethylation. Moreover, many researchers using human and animal models proposed that HHcy leads to hyper/hypomethylation in a tissue-specific manner [149–151]. Cancer patients often show high Hcy levels, suggesting a possible link between Hcy-mediated hyper/hypomethylation and the causation of different types of cancer. Indeed, a study found HHcy-mediated hypermethylation of CpG islands located in the promoter of the ER $\alpha$  gene in breast cancer cell cells [152]. Interestingly, Zhang et al. showed that

10 and 30  $\mu\text{mol/L}$  Hcy levels induced hypomethylation, whereas 100 and 300  $\mu\text{mol/L}$  Hcy levels induced hypermethylation in the promoter of the Dimethylarginine Dimethylaminohydrolase 2 (DDAH2) gene [153]; this result suggests that hyper/hypomethylation may also depend on levels of Hcy production. Additionally, the methylation pattern also depends on many other factors such as DNA replication, chromatin accessibility, local availability of SAM, nutritional factors (folate supplementation), and aging [154]. Although hypo/hypermethylation of DNA depends on the HHcy state and tissue types [62,149–151], very limited studies have been carried out so far to show the association of HHcy and causation, progression and metastasis of cancer.

#### 4.3.2. Hcy-Mediated Histone Modification and Cancer

Histone protein is present in the nucleosomes, where DNA molecules wrap around at specific intervals [155]. Many post-translation modifications (acetylation, methylation, phosphorylation, ubiquitination, and sumoylation) of histones lead to gene activation and inactivation [156]. These modifications are dynamic; one set of enzymes (called writers) can put down these activation/repressive marks, and another group of enzymes (erasers) can reverse these marks [156]. Although alteration of histone modifications can cause upregulation or downregulation of specific gene expression, minimal studies have been conducted on HHcy-mediated histone modification and its associated pathology in cancer. Since HHcy can inhibit SAM-dependent methyltransferases via a negative feedback mechanism [157], it can be concluded that HHcy can also alter histone methylation patterns that might influence tumor formations. Indeed, some studies found that these histone modifications act as drivers for different types of cancer, as reviewed by Levi A Garraway et al. and Kristian Helin et al. [158,159]. However, histone modifications also vary between cell types [160], so various histone modifications may lead to different types of cancer. Which factors and how these modifications have been regulated in different cell types that lead to different types of cancers is something that needs to be explored in the near future.

#### 4.3.3. Hcy-Mediated RNA Interference and Cancer

Earlier researchers used to think that RNA had only a housekeeping function (tRNAs and rRNAs) and a messenger function (mRNA) [161]; however, recent studies have found many new classes of regulatory non-coding RNAs. Some important non-coding RNAs are micro-RNA, endogenous small interfering RNAs (endo-siRNAs), PIWI-associated RNAs (piRNAs), and long non-coding RNAs. The discovery of non-coding RNAs has completely updated our understanding of cancer research [162]. The prognosis value of microRNA (miRNA) and long non-coding RNA (lncRNA) are widely reported in cancers [163,164]. Many studies showed that HHcy interferes with microRNA regulation and long non-coding RNA (lncRNA) [165], suggesting a link between HHcy and abnormal gene expression in cancer progression. Although most cancer research has focused on the abnormal expression of oncogenes or tumor suppressor genes, 97% of the human genome consists of non-coding sequences, leading researchers to investigate this dark matter of tumorigenesis. Non-coding RNAs can induce tumorigenesis and tumor progression via transcriptional and post-transcriptional modification, chromatin remodeling, and signal transduction. Although, to date, most of the integration of non-coding RNAs and tumorigenesis is still unknown, current research has started uncovering the complex network of the interaction of non-coding RNAs and how they modify the expression of oncogenes and tumor suppressor genes. These non-coding RNAs present in a tissue-specific manner and are considered as diagnostic, prognostic, and therapeutic targets in different diseases. There is growing research about the dysregulation of Circular RNAs (circRNAs) in cancer [166–169]. Recent reports show that circRNAs play essential roles in prostate cancer's progression, proliferation, and epithelial-mesenchymal transition (EMT) [170]. In our previous studies, we noticed that under HHcy conditions circRNAs profile differently than in normal conditions [166,167,171]. HHcy-mediated, non-coding RNAs vary in different tissue types, suggesting more research is needed to identify specific changes in non-coding RNA based on the cancer types.




#### 4.4. Hcy-Mediated H<sub>2</sub>S Production and Risk of Cancer

H<sub>2</sub>S was previously thought of as a toxic gas. However, recent studies found that other than from gut microbiota, H<sub>2</sub>S is produced inside a cell via Hcy metabolism [172]. H<sub>2</sub>S acts as a gasotransmitter like other gasotransmitters (for example, nitric oxide) and has a cytoprotective role [17]. H<sub>2</sub>S plays a crucial role in reducing oxidative and ER stress during HHcy conditions [7], suggesting a favorable role of H<sub>2</sub>S in cancer progression. Many studies also reported the role of H<sub>2</sub>S in cell proliferation, viability, and migration of cancer cells [173]. The CBS gene in Hcy metabolism typically catalyzes the condensation of serine with Hcy to produce cystathionine (in a transsulfuration reaction), whereas it produces H<sub>2</sub>S via  $\beta$ -elimination and  $\beta$ -replacement reactions [174]. Both  $\beta$ -elimination (catalysis of cysteine) and  $\beta$ -replacement (reaction of L-cysteine and 2-mercaptoethanol) reactions produce H<sub>2</sub>S. Many clinical studies have shown that there is CBS overexpression and increased H<sub>2</sub>S production in many cancer types [175,176]. Previous studies showed that tumor cells have a high proliferative rate, producing a massive amount of reactive oxygen species (ROS) [177] and needing neoangiogenesis [178]. In contrast, many studies have suggested that H<sub>2</sub>S reduces oxidative stress, induces cell proliferation and viability, and improves neoangiogenesis [7,48,172,179]. As SAM is an allosteric activator of CBS that binds to the regulatory domain of CBS and regulates H<sub>2</sub>S production, indeed, it helps in the growth of tumor cells [180]. Therefore, future strategies to treat cancer patients should involve modulation of CBS and H<sub>2</sub>S levels.

#### 5. Multifactorial Role of H<sub>2</sub>S in Cancer


Recent studies showed that H<sub>2</sub>S production helps induce cancer cell proliferation, viability, invasion, and metastasis [18]. Increasing levels of H<sub>2</sub>S have been proposed to induce cancer development by regulating a wide variety of cancer-related processes; this suggests that targeting H<sub>2</sub>S production could be a beneficial tool for cancer treatment. This section focuses on how H<sub>2</sub>S plays a role in cancer progression by targeting different processes, including oxidative stress, anti-apoptosis, DNA repair, tumor growth, cancer metabolism, metastasis, and angiogenesis (summarized in Figure 3).



**Figure 3.** Different signaling pathways showing the multifactorial effects of H<sub>2</sub>S in cancer development. The cartoons represent the six cancer hallmarks influenced by H<sub>2</sub>S/H<sub>2</sub>S-mediated protein persulfidation.

5.1. H<sub>2</sub>S Production via Dysregulation of CBS, CSE, and 3MST Genes in Cancer

H<sub>2</sub>S is produced endogenously through the transsulfuration pathway (involving CBS, CSE, and 3MST enzymes) of Hcy metabolism, as shown in Figure 4 [181]. Three enzymes that catalyze H<sub>2</sub>S production are often found dysregulated in cancer, as shown in Table 3.



**Figure 4.** Signaling pathways of H<sub>2</sub>S production via Hcy metabolism. In the cytoplasm, H<sub>2</sub>S is produced from Hcy with the help of the CBS and CSE enzymes, whereas in mitochondria, H<sub>2</sub>S is produced with the help of the 3-MST enzyme.

**Table 3.** Association of different H<sub>2</sub>S-producing enzymes in different cancer types.

Enzymes	Cancer Types	Upregulation/Downregulation	Reference
CBS	Colon Cancer	Upregulation	[182]
	Ovarian Cancer	Upregulation	[176]
	Breast Cancer	Upregulation	[183]
	Thyroid Cancer	Upregulation	[184]
	Gallbladder Adenocarcinoma	Upregulation	[185]
	Hepatocellular Carcinoma	Downregulation	[186]
	Gastrointestinal Cancer	Downregulation	[187]
CSE	Breast Cancer	Upregulation	[188]
	Prostate Cancer	Upregulation	[189]
	Gastric Cancer	Upregulation	[190]
	Bladder Cancer	Upregulation	[191]
	Hepatoma	Upregulation	[192]
	Colon Cancer	Upregulation	[193]
3MST	Renal Cell Carcinoma	Downregulation	[194]
	Glioma Tumor	Upregulation	[195]
	Colon Cancer	Upregulation	[196]

### 5.1.1. Dysregulation of CBS in Cancer

The main rate-limiting enzyme of the trans-sulphuration reaction of Hcy-metabolism is CBS, which catalyzes H<sub>2</sub>S production by driving the beta-replacement. The CBS gene is often found to be upregulated in colon cancer, ovarian cancer, breast cancer, thyroid cancer, and gallbladder adenocarcinoma tissues [182,184,185,197]. A study found that DNA methylation of the CBS promoter favors colon cancer progression [198]. SAM can allosterically activate the CBS gene to favor the cell proliferation of colon cancer cells [199]. Additionally, CBS can also be controlled via its redox sensitivity through the <sup>272</sup>CXXC<sup>275</sup> motif [200]. The high proliferation of cancer cells creates redox stress conditions inside the cells, which activates the CBS gene to produce H<sub>2</sub>S through the <sup>272</sup>CXXC<sup>275</sup> motif [200]. Although some studies showed that CBS expression is downregulated in glioma tumor cells, gastrointestinal cancer cells [186,187,201], and hepatocellular carcinoma, alternatively, reduced CBS expression upregulates the 3-MST gene in glioma tumor cells [202].

### 5.1.2. Dysregulation of CSE in Cancer

CSE is one of the three H<sub>2</sub>S-producing enzymes in the transsulfuration pathway of Hcy metabolism. CSE has been upregulated in multiple cancer types, including prostate cancer, gastric cancer, and melanoma cells [190,203,204]. CSE was found to be induced by oxidative stress, ER stress, Golgi stress, inflammation, and starvation [205]. Unlike CBS, CSE can be upregulated transcriptionally via cellular stress response [206]. Under oxidative stress condition, nuclear factor (erythroid-derived 2)-like 2 (Nrf2) induces CSE expression through binding to its antioxidant response element (ARE) at 5'-untranslated regions (UTR), which in turn induce H<sub>2</sub>S production [207]. Overexpression of another transcription factor, specificity protein (SP) 1, induces H<sub>2</sub>S generation via binding to the CSE promoter [208]. Similarly, another study showed that tumor necrosis factor  $\alpha$  (TNF $\alpha$ ) induces H<sub>2</sub>S production through SP1-mediated CSE promoter binding [209]. In prostate cancer, a study found that CSE over-expression increased H<sub>2</sub>S production that led to the activation of nuclear factor- $\kappa$ B (NF- $\kappa$ B)-mediated interleukin 1 $\beta$  (IL-1 $\beta$ ) signaling, resulting in enhanced cell invasion, angiogenesis, lymphangiogenesis, tumor growth, and metastasis [210]. Moreover, the upregulation of CSE by the STAT3 pathway increased breast cancer cell proliferation, growth, and migration [188]. Similarly, the upregulation of CSE by the Wnt/ $\beta$ -catenin pathway increased cell proliferation in colon cancer [193] whereas by extracellular signal-regulated protein kinase 1/2 (ERK1/2) pathway increased cell proliferation in liver cancer [192].

### 5.1.3. Dysregulation of 3MST in Cancer

3MST is another H<sub>2</sub>S-producing enzyme primarily regulated through a redox-sensitive mechanism [206]. As oxidative stress is one of the characteristics of cancer cells, it seems that cancer cells primarily depend on 3MST for H<sub>2</sub>S production. During oxidative stress condition, 3MST becomes activated via oxidation at Cys<sup>247</sup> and subsequently produces H<sub>2</sub>S to control cellular homeostasis [211]. Indeed, pharmacological inhibition of 3MST has been found to reduce cell proliferation, migration, and bioenergetics in colon cancer cells [212]. More research is needed to understand how different cancer types regulate 3MST to maintain their cellular redox balance.

## 5.2. H<sub>2</sub>S-Mediated Redox Balance in Cancer

As cancer cells have a high proliferative rate, they produce many free radicals [213]. There is the possibility that cancer cells upregulate H<sub>2</sub>S-producing enzymes in order to handle oxidative stress. Multiple studies demonstrated the cytoprotective effects of H<sub>2</sub>S in different *in vitro* models, all relating to its ability to neutralize a variety of reactive species [214–216] and reduction of a disulfide bond in proteins [217,218]. H<sub>2</sub>S in water dissociates into H<sup>+</sup>, HS<sup>-</sup>, and S<sup>2-</sup> ions. HS<sup>-</sup> has the capacity to scavenge ROS. H<sub>2</sub>S itself has also been recognized to be a reducing agent, as it can react directly with and quench the superoxide anion (O<sup>2-</sup>) [219,220] and free radicals like peroxynitrite [221] as well as

other ROS in vitro. Micro concentrations of H<sub>2</sub>S generated from Na<sub>2</sub>S/NaHS were found to neutralize free oxyradicals [222], peroxynitrite [214], hypochlorous acid [215], and Hcy [216] in in vitro conditions. There is no sulfide receptor in mammalian cells that is responsible for the biological actions of sulfide; hence sulfide, as a thiol with strong reducing activities, may also be a redox-controlling molecule similar to other small thiols, such as cysteine and GSH [214,223]. A study using primary cultures of neurons found that H<sub>2</sub>S increases cellular GSH levels by enhancing gamma-glutamylcysteine synthetase activity and upregulating cystine transport [223]. Similarly, another study reported that 100 μM NaHS induces glutamate uptake by assisting glial glutamate transporter-1 (GLT-1) and enhances cysteine transport and GSH synthesis [224]. In support of this effect, multiple studies demonstrated that H<sub>2</sub>S induces cellular GSH in the brain [225], spinal cord [226], heart [227], lung [228], kidney [229], liver [228], and gastrointestinal tract [230,231]. Moreover, recent reports suggested that H<sub>2</sub>S could attenuate cellular oxidative stress by improving the activities of catalase [227,232–234] and glutathione peroxidase [235–237].

### 5.3. H<sub>2</sub>S-Mediated Recovery of Hypoxia in Cancer

Hypoxia is one of the hallmarks of solid tumors. H<sub>2</sub>S has been widely studied for its effects on the regulation of oxygen homeostasis via inhibiting HIF-1α activation [238]. Different studies found upregulation of H<sub>2</sub>S-producing enzymes under hypoxia conditions and its associated cancer progression [239,240]. In addition to this, our previous studies found that under hypoxia conditions, H<sub>2</sub>S induces neoangiogenesis via upregulation of the PPAR-c/HIF-1α signaling pathway [48]. Similarly, another study identified that H<sub>2</sub>S enhances HIF-1α expression via the downregulation of miR-640 [241]. In non-small cell lung cancer, a study proposed that H<sub>2</sub>S might activate HIF-1α via the PI3K/AKT pathway leading to angiogenesis [242]. Similarly, another study showed that under hypoxia, cancer cells produce H<sub>2</sub>S via induction of CSE to facilitate angiogenesis [243].

### 5.4. H<sub>2</sub>S-Mediated Recovery of Apoptosis in Cancer

Apoptosis is the process of cell death that happens naturally due to physiological or environmental stress [2]. Inhibition of apoptosis is one of the hallmarks of cancer progression that allows cancer cells to survive under various stresses [244]. Recent studies found that H<sub>2</sub>S has an antiapoptotic property in various cell types [17]. Different studies also found that cancer cells produce more H<sub>2</sub>S to evade apoptosis [245–248]. These studies suggest that, like classical antioxidants (for example, GSH), H<sub>2</sub>S inhibits apoptosis in cancer cells via scavenging ROS and reactive nitrogen species (RNS). The cancer cell has a high metabolic activity due to the high proliferative rate, and this leads to the generation of ROS and RNS. So, to recover from this oxidative stress condition, cancer cells need to produce more antioxidants like H<sub>2</sub>S to create profound antioxidant protection [206].

H<sub>2</sub>S not only suppresses apoptosis through the reduction in oxidative stress but is also found to activate various antiapoptotic pathways, including NF-κB [209], kelch-like ECH-associated protein 1 (Keap1) [249], and mitogen-activated protein kinase kinase 1 (MEK1) [250]. When NF-κB signaling becomes activated, it further activates multiple antiapoptotic genes, including the X-linked inhibitor of apoptosis protein (XIAP), cellular Inhibitors of Apoptosis Proteins (cIAPs), and the B-cell lymphoma 2 (Bcl-2) [251]. In contrast, Keap1 is mediated by persulfidation by H<sub>2</sub>S; after persulfidation, Keap1 acts as an adaptor for the Keap1-Cul3-RBX1 E3 ligase complex, which targets Nrf2 to proteasomal degradation [252]. Nrf2 acts as a transcription factor for genes containing antioxidant response elements (AREs) to suppress apoptosis in cancer cells [252]. The other process of H<sub>2</sub>S-mediated inhibition of apoptosis is via the activation of MEK1, which is one of the classical MAP kinase family proteins. MEK1 generally suppresses apoptosis via inhibition of the expressions of apoptotic-related proteins, including Bad, Bim-EL, Caspase 9, MCL-1, and TNFR [253].

### 5.5. H<sub>2</sub>S-Mediated DNA Repair in Cancer

H<sub>2</sub>S has been found to activate the DNA repair process via MEK1/Protein poly [ADP-ribose] polymerase 1 (PARP1)-mediated signaling pathways in cancer cells [250]. After the persulfidation of MEK1 at Cys<sup>341</sup> residue by H<sub>2</sub>S, MEK1 translocates to the nucleus to stimulate PARP-1. PARP-1 is widely known as a sensor of DNA single- or double-strand breaks [254]. This suggests that cancer cells may use H<sub>2</sub>S to recover from DNA damage during proliferation. Moreover, H<sub>2</sub>S has also been found to help in mitochondrial DNA (mtDNA) repair via persulfidation on mt-specific DNA repair enzymes EXOG at Cys<sup>76</sup> [255], which suggests that cancer cells may skip the apoptosis process via H<sub>2</sub>S-mediated recovery of DNA damage.

### 5.6. H<sub>2</sub>S-Mediated Tumor Growth and Metastasis in Cancer

Different studies found that higher levels of H<sub>2</sub>S in multiple cancer types [182,188,210,212] and inhibition of H<sub>2</sub>S production via suppression of CBS or CSE activities cause a reduction in tumor growth in multiple cancer types [182,210,255]. This suggests the critical role of H<sub>2</sub>S in the growth, proliferation, and survival of cancer cells. In addition, many studies found that endogenous H<sub>2</sub>S promotes cancer cell migration and invasion in multiple cancer types [210,242,256,257]. These studies showed that H<sub>2</sub>S promotes the metastasis process via various mechanisms, which include induction of epithelial-to-mesenchymal transition (EMT). Moreover, NF-κB is a key player in cancer metastasis; as H<sub>2</sub>S induces the persulfidation of NF-κB, it helps p65 to translocate into the nucleus and induce expressions of the metastatic promoting gene [210].

### 5.7. H<sub>2</sub>S-Mediated Metabolism in Cancer

Cancer cells have a very high proliferative rate, so they require more ATP production to maintain cellular energetics [258]. Endogenous H<sub>2</sub>S production was shown to act as a metabolic substrate for mitochondrial ATP production in cancer cells [199]. Moreover, H<sub>2</sub>S was found to increase the catalytic activity of mitochondria ATP synthase via persulfidation of ATP synthase (ATP5A1), which may induce mitochondrial ATP production [258]. To support their high growth rates, cancer cells preferentially convert glucose to lactate by aerobic glycolysis even in sufficient O<sub>2</sub> (Warburg effect). In this process, lactate dehydrogenase A (LDHA) acts as a key player, and it is found that cancer cells induce LDHA activity via the persulfidation of LDHA at Cys<sup>163</sup>. Consistent with this, depletion of H<sub>2</sub>S production via knockdown of CBS was also found to reduce ATP production in cancer cells [176,182].

### 5.8. H<sub>2</sub>S-Mediated Angiogenesis in Cancer

Angiogenesis is one of the hallmarks of cancer; during tumor growth and metastasis, tumor cells secrete proangiogenic factors such as VEGF [259]. Previous studies found that H<sub>2</sub>S induced angiogenesis under different disease conditions [48], including cancer [243]. Similarly, suppressing H<sub>2</sub>S production via silencing the CBS gene reduced angiogenesis in colon and ovarian cancer [176,182]. Additionally, suppression of H<sub>2</sub>S production via silencing another H<sub>2</sub>S-producing enzyme, CSE, was found to block angiogenesis [210]. Moreover, H<sub>2</sub>S was found to promote angiogenesis via activation of HIF-1α [197]. Additionally, H<sub>2</sub>S-mediated induction of angiogenesis has been found via NF-κB/IL-1β, PI3K/AKT, and MAPK signaling pathways [199,210].

### 5.9. H<sub>2</sub>S-Mediated Reduction in ER Stress in Cancer

As cancer cells have a high proliferation rate, they create different gene mutations, produce more misfolded proteins, and induce ER stress response [260]. As H<sub>2</sub>S was found to reduce ER stress in different disease conditions [7,261–263], it suggests that cancer cells may produce more H<sub>2</sub>S to recover from ER stress. In addition, as cancer cells mainly depend on the methylation cycle, this also produces a high amount of Hcy, which induces homocysteinylation of protein and further activates ER stress [264]. There is also the possibility that H<sub>2</sub>S can reverse protein homocysteinylation [265].

## 6. Current Cancer Therapeutics Targeting the Hcy and H<sub>2</sub>S Signaling and Their Limitations

Current treatment options for cancer are based on specific types of cancer and the stage of cancer; these include chemotherapy, radiation therapy, immunotherapy, and targeted therapy [266]. While treatment increases the lifespan of many patients, it is also associated with many side effects that will determine the health consequences. Also, the efficacy of these treatment options is limited by the resistance that patients develop [267]. As chemotherapy has many side effects due to the property of killing normal healthy cells, recent treatment is shifting gears toward targeted therapy approaches.

Methionine is an essential amino acid, and many tumor cells show dependence on exogenous sources of methionine [4]. Studies showed that methionine restriction inhibits cancer cell growth proliferation while normal cells remain unaffected [4]. In addition, methionine restriction showed enhanced efficiency of chemotherapy and radiotherapy in animal models [268]. A previous study showed that methionine restriction for an average of 17 weeks is safe and feasible in patients with advanced metastatic cancer [14].

Moreover, there have been many drugs developed that target the methionine cycle, but none of them showed clinical success. Antifolate drugs (for example, methotrexate) that interfere with the folate cycle have shown limited clinical efficiency due to side effects and resistance [269,270]. As the methylation cycle is essential for normal cells, these drugs kill both cancer and healthy cells. However, small molecule inhibitors that target serine synthesis pathways have been successful in *in vitro* and animal studies [271,272]. However, in order to reduce side effects, the drug used has to be specific to the particular cancer. For small molecule inhibitors that inhibit PHGDH (for example, NCT-503, CBR-5884), the tumor has to be fully addicted to PHGDH. Also, it needs to be ensured that this drug does not interfere with any other signaling pathways critical for signaling. If any type of tumor is not fully dependent on a specific pathway, that means the cancer cells may be using another source for that specific pathway. For targeting the serine synthesis pathway, if any specific cancer cell lines do not respond to the drug, these cells may be using exogenous serine supplementation. So, to target this cancer type with this drug, we should also consider the external source of nutrients/diet. Another type of mechanism is called the compensatory mechanism, by which cancer cells become resistant to specific drugs. For example, any drug targeting mitochondrial methylenetetrahydrofolate dehydrogenase (MTHFD1L) cancer cells can compensate using cytoplasmic MTHFD1 [273].


There are variable reports so far documented when it comes to targeting H<sub>2</sub>S metabolism. Lower doses of H<sub>2</sub>S donor compounds were found to have pro-cancer activity by different mechanisms [274], whereas higher doses had anticancer activity due to uncontrolled intracellular acidification [275–277]. Various H<sub>2</sub>S donor compounds (for example, NaHS, Na<sub>2</sub>S, GYY4137) tested preclinically for their anticancer property [275–277]. In contrast, as many studies showed, endogenous H<sub>2</sub>S has beneficial effects for tumor growth and metastasis, and inhibiting endogenous production of H<sub>2</sub>S (via targeting H<sub>2</sub>S-producing enzymes) may be a good strategy. DL-propargylglycine (PAG) is an inhibitor of CSE that showed limited cell permeability [218] and non-selective inhibition of other enzymes [278–280]. Another inhibitor of H<sub>2</sub>S-producing enzymes is aminoxy acetic acid (AOAA), which is also found to inhibit cysteine aminotransferase (CAT) [281]. HMPSNE is an inhibitor that targets the 3rd H<sub>2</sub>S-producing enzyme 3MST, showed the highest selectivity for 3MST [31,282], and was found to inhibit cell proliferation of colon cancer [212,283]. In order to make a more efficient drug that inhibits H<sub>2</sub>S production, more research is needed.

Although targeting H<sub>2</sub>S production showed promise, there are a few limitations. Firstly, many previous studies that targeted H<sub>2</sub>S production used the pharmacological inhibitor AOAA (a CBS inhibitor). However, AOAA showed nonspecific inhibition of CSE, 3MST, and over thirty other cellular enzymes [284]. Similarly, another H<sub>2</sub>S production inhibitor, β-cyano-alanine, showed suboptimum specificity [285]. Secondly, there are functional differences between H<sub>2</sub>S production enzymes in different cancer types. For example, in prostate cancer, mutant CSE was found to be lowly invasive but did not interfere with cell

migration capacity [210], suggesting the mutation-specific targeting of H<sub>2</sub>S production will be necessary for future therapeutics.

#### *A Hypothesis of Targeting the Hcy and H<sub>2</sub>S Balance for Cancer Treatment and Its Application*

Due to the high proliferative rate, cancer cells require an external source of methionine for protein formation, methylation reaction (epigenetic alteration), and the production of H<sub>2</sub>S (antioxidant). When cancer cells use the methionine cycle, it produces a massive amount of Hcy, which is toxic for the growth of the tumors. As previous studies found that high SAM levels act as an allosteric inhibitor of MTHFR (involved in the folate cycle) and activator of CBS, so when cancer cells produce high SAM levels, it prevents Hcy from entering the remethylation pathway rather than allowing excess Hcy to shuttle to the transsulfuration pathway to produce H<sub>2</sub>S [71–73]. This production of high H<sub>2</sub>S in cancer cells helps them to survive, proliferate, grow, and metastasize. Although many therapeutic strategies have been developed either by methionine restriction or targeting different enzymes of the methionine cycle, folate cycle, and transsulfuration pathway, none of these treatment strategies showed effectiveness in clinical studies. So, in the future, more research is required where we can utilize their dependence on the methionine cycle and target specific enzymes to treat cancer. So far, we have noticed that cancer cells depend on the methionine cycle more, so if we can target both the transsulfuration pathway (via CBS) and the remethylation pathway at the same time, as shown in Figure 5, then these cells will build up toxic Hcy and inhibit the production of H<sub>2</sub>S. High levels of Hcy will induce apoptosis, protein oxidation, and oxidative and ER stress and inhibit angiogenesis, whereas low levels of H<sub>2</sub>S will inhibit cancer growths; as a result, tumor progression will be inhibited due to the effects of high Hcy and low levels of antioxidants like H<sub>2</sub>S.



**Figure 5.** Cartoon diagram showing how homocysteine and H<sub>2</sub>S balance can be targeted for cancer treatment. Targeting the transsulfuration and remethylation pathway in cancer cells will build up highly toxic homocysteine inside the cells. Consequently, cancer progression will be inhibited via apoptosis, poor angiogenesis, protein oxidation, and oxidative and ER stress.

Efforts to interfere with the methylation cycle in different cancers have reached a plateau, with only incrementally effective inhibitors developed to date. In order to overcome this barrier and develop highly effective inhibitors, we need to understand how to target this Hcy and H<sub>2</sub>S signaling more precisely with minimal side effects. Based on the above discussion, although it is apparent that targeting Hcy and H<sub>2</sub>S balance is beneficial for cancer treatment, there are however no studies have been carried out that exploit this circuit. This extensive review article will likely lead us and many in academia and industry to develop next-generation therapeutic agents targeting the blocking of H<sub>2</sub>S production and Hcy remethylation. The significance and impact would be profound in increasing efficacy and reducing toxicity for a large number of cancer patients where targeted therapy was shown to be non-effective. For example, in treating triple-negative breast cancer, this treatment strategy will be a good option as there is no other oncogene-driven monotherapy available. Similarly, cancer types that are more dependent on the methionine cycle will be the best option to use this strategy. Another exciting cancer treatment aspect that was not covered in this review is Hcy-mediated epigenetic alteration and H<sub>2</sub>S-mediated polysulfide production in cancer. So, a better understanding of their signaling in cancer will undoubtedly facilitate better treatment for cancer patients.

## 7. Conclusions

Given that cancer cells depend on the methionine cycle for their methylation reaction and H<sub>2</sub>S production, many researchers tried different strategies to target these signaling pathways. Unfortunately, none of the strategies turned out beneficial for cancer treatment. Based on current understanding, it is noted that indefinite targeting of the methionine cycle, either via a methionine restriction diet or targeting different enzymes of the methionine cycle, is not feasible due to the development of resistance, non-responsiveness, and numerous side effects. However, targeting H<sub>2</sub>S production showed to be somewhat promising based on its effects on cancer progression via inhibition apoptosis, oxidative stress, ER stress, and stimulation of the DNA repair process, cancer metabolism, tumor growth, and metastasis. Again, this strategy did not benefit cancer treatment due to nonspecific targeting. Therefore, for future prospects, it is necessary to target the transsulfuration pathway for blocking H<sub>2</sub>S production and the remethylation pathway to build up toxic Hcy. As we noticed, Hcy has detrimental effects on cells via apoptosis, protein oxidation, lipid peroxidation, poor angiogenesis, oxidative stress, and ER stress. So, excess Hcy build-up will not be able to recover via simultaneous blocking of H<sub>2</sub>S production, which leads to the regression of tumor growth. However, more research is anticipated to test this proof of concept for cancer treatment.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The author declares no conflict of interest.

## Abbreviations

SAH	S-Adenosyl Homocysteine
Hcy	Homocysteine
HHcy	Hyperhomocysteinemia
SAM	S-Adenosyl Methionine
H <sub>2</sub> S	Hydrogen Sulfide
GSH	Glutathione
ROS	Reactive Oxygen Species
ER	Endoplasmic Reticulum
MAT	Methionine Adenosyl Transferase
CBS	Cystathionine B-Synthase
CSE	Cystathionine $\Gamma$ -Lyase



MTHFR	Methylenetetrahydrofolate Reductase
MTRR	Methionine Synthase Reductase
MTR	Methionine Synthase
MTHFD	Methylenetetrahydrofolate Dehydrogenase
BHMT	Betaine Homocysteine Methyltransferase
TYMS	Thymidylate Synthase
TCN2	Transcobalamin 2
MTHFD1L	Methylenetetrahydrofolate dehydrogenase
DNMTS	DNA Methyltransferases
VSMCS	Vascular Smooth Muscle Cells
DDAH2	Dimethylarginine Dimethylaminohydrolase 2
HMT	Histone Methyltransferase
lncRNA	Long Non-Coding RNA
miRNA	MicroRNA
circRNA	CircularRNA
NF-κB	Nuclear factor kappa-light-chain-enhancer of activated B cells
Keap1	Kelch-like ECH-associated protein 1
MEK1	Mitogen-activated protein kinase kinase1
XIAP	X-linked inhibitor of apoptosis protein
cIAPs	Cellular Inhibitors of Apoptosis Proteins
Bcl-2	B-cell lymphoma 2 gene
AREs	Antioxidant Response Elements

## References

- Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. *Lancet* **2016**, *388*, 1459–1544. [[CrossRef](#)]
- Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. *Cell* **2011**, *144*, 646–674. [[CrossRef](#)]
- Altea-Manzano, P.; Cuadros, A.M.; Broadfield, L.A.; Fendt, S.M. Nutrient metabolism and cancer in the in vivo context: A metabolic game of give and take. *EMBO Rep.* **2020**, *21*, e50635. [[CrossRef](#)]
- Cellarier, E.; Durando, X.; Vasson, M.P.; Farges, M.C.; Demiden, A.; Maurizis, J.C.; Madelmont, J.C.; Chollet, P. Methionine dependency and cancer treatment. *Cancer Treat. Rev.* **2003**, *29*, 489–499. [[CrossRef](#)] [[PubMed](#)]
- Dunn, R.; McCoy, J.; Simsek, M.; Majumdar, A.; Chang, S.H.; Rajbhandary, U.L.; Khorana, H.G. The bacteriorhodopsin gene. *Proc. Natl. Acad. Sci. USA* **1981**, *78*, 6744–6748. [[CrossRef](#)] [[PubMed](#)]
- Navik, U.; Sheth, V.G.; Khurana, A.; Jawalekar, S.S.; Allawadhi, P.; Gaddam, R.R.; Bhatti, J.S.; Tikoo, K. Methionine as a double-edged sword in health and disease: Current perspective and future challenges. *Ageing Res. Rev.* **2021**, *72*, 101500. [[CrossRef](#)]
- Majumder, A.; Singh, M.; Behera, J.; Theilen, N.T.; George, A.K.; Tyagi, N.; Metreveli, N.; Tyagi, S.C. Hydrogen sulfide alleviates hyperhomocysteinemia-mediated skeletal muscle atrophy via mitigation of oxidative and endoplasmic reticulum stress injury. *Am. J. Physiol. Cell Physiol.* **2018**, *315*, C609–C622. [[CrossRef](#)]
- Majumder, A.; Behera, J.; Jeremic, N.; Tyagi, S.C. Hypermethylation: Causes and Consequences in Skeletal Muscle Myopathy. *J. Cell. Biochem.* **2017**, *118*, 2108–2117. [[CrossRef](#)]
- Combs, J.A.; DeNicola, G.M. The Non-Essential Amino Acid Cysteine Becomes Essential for Tumor Proliferation and Survival. *Cancers* **2019**, *11*, 678. [[CrossRef](#)]
- Wanders, D.; Hobson, K.; Ji, X. Methionine Restriction and Cancer Biology. *Nutrients* **2020**, *12*, 684. [[CrossRef](#)]
- Peng, H.; Yan, Y.; He, M.; Li, J.; Wang, L.; Jia, W.; Yang, L.; Jiang, J.; Chen, Y.; Li, F.; et al. SLC43A2 and NFκB signaling pathway regulate methionine/cystine restriction-induced ferroptosis in esophageal squamous cell carcinoma via a feedback loop. *Cell Death Dis.* **2023**, *14*, 347. [[CrossRef](#)] [[PubMed](#)]
- Khairan, P.; Sobue, T.; Eshak, E.S.; Zha, L.; Kitamura, T.; Sawada, N.; Iwasaki, M.; Inoue, M.; Yamaji, T.; Shimazu, T.; et al. Association of dietary intakes of vitamin B12, vitamin B6, folate, and methionine with the risk of esophageal cancer: The Japan Public Health Center-based (JPHC) prospective study. *BMC Cancer* **2021**, *21*, 982. [[CrossRef](#)] [[PubMed](#)]
- Guo, H.; Lishko, V.K.; Herrera, H.; Groce, A.; Kubota, T.; Hoffman, R.M. Therapeutic tumor-specific cell cycle block induced by methionine starvation in vivo. *Cancer Res.* **1993**, *53*, 5676–5679.
- Epner, D.E.; Morrow, S.; Wilcox, M.; Houghton, J.L. Nutrient intake and nutritional indexes in adults with metastatic cancer on a phase I clinical trial of dietary methionine restriction. *Nutr. Cancer* **2002**, *42*, 158–166. [[CrossRef](#)]
- George, A.K.; Singh, M.; Homme, R.P.; Majumder, A.; Sandhu, H.S.; Tyagi, S.C. A hypothesis for treating inflammation and oxidative stress with hydrogen sulfide during age-related macular degeneration. *Int. J. Ophthalmol.* **2018**, *11*, 881–887. [[CrossRef](#)]
- Kaiser, P. Methionine Dependence of Cancer. *Biomolecules* **2020**, *10*, 568. [[CrossRef](#)]
- Majumder, A.; Singh, M.; George, A.K.; Tyagi, S.C. Restoration of skeletal muscle homeostasis by hydrogen sulfide during hyperhomocysteinemia-mediated oxidative/ER stress condition. *Can. J. Physiol. Pharmacol.* **2019**, *97*, 441–456. [[CrossRef](#)]
- Hellmich, M.R.; Szabo, C. Hydrogen Sulfide and Cancer. *Handb. Exp. Pharmacol.* **2015**, *230*, 233–241. [[CrossRef](#)] [[PubMed](#)]

19. Newman, A.C.; Maddocks, O.D.K. One-carbon metabolism in cancer. *Br. J. Cancer* **2017**, *116*, 1499–1504. [[CrossRef](#)] [[PubMed](#)]
20. Hasan, T.; Arora, R.; Bansal, A.K.; Bhattacharya, R.; Sharma, G.S.; Singh, L.R. Disturbed homocysteine metabolism is associated with cancer. *Exp. Mol. Med.* **2019**, *51*, 1–13. [[CrossRef](#)]
21. Skibola, C.F.; Smith, M.T.; Kane, E.; Roman, E.; Rollinson, S.; Cartwright, R.A.; Morgan, G. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. *Proc. Natl. Acad. Sci. USA* **1999**, *96*, 12810–12815. [[CrossRef](#)] [[PubMed](#)]
22. He, L.; Shen, Y. MTHFR C677T polymorphism and breast, ovarian cancer risk: A meta-analysis of 19,260 patients and 26,364 controls. *OncoTargets Ther.* **2017**, *10*, 227–238. [[CrossRef](#)] [[PubMed](#)]
23. Li, X.L.; Xu, J.H. MTHFR polymorphism and the risk of prostate cancer: A meta-analysis of case-control studies. *Prostate Cancer Prostatic Dis.* **2012**, *15*, 244–249. [[CrossRef](#)] [[PubMed](#)]
24. Mbemi, A.; Khanna, S.; Njiki, S.; Yedjou, C.G.; Tchounwou, P.B. Impact of Gene-Environment Interactions on Cancer Development. *Int. J. Environ. Res. Public Health* **2020**, *17*, 8089. [[CrossRef](#)]
25. Chen, J.; Giovannucci, E.; Kelsey, K.; Rimm, E.B.; Stampfer, M.J.; Colditz, G.A.; Spiegelman, D.; Willett, W.C.; Hunter, D.J. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. *Cancer Res.* **1996**, *56*, 4862–4864.
26. Ma, E.; Iwasaki, M.; Junko, I.; Hamada, G.S.; Nishimoto, I.N.; Carvalho, S.M.; Motola, J., Jr.; Laginha, F.M.; Tsugane, S. Dietary intake of folate, vitamin B6, and vitamin B12, genetic polymorphism of related enzymes, and risk of breast cancer: A case-control study in Brazilian women. *BMC Cancer* **2009**, *9*, 122. [[CrossRef](#)]
27. Suzuki, T.; Matsuo, K.; Sawaki, A.; Mizuno, N.; Hiraki, A.; Kawase, T.; Watanabe, M.; Nakamura, T.; Yamao, K.; Tajima, K.; et al. Alcohol drinking and one-carbon metabolism-related gene polymorphisms on pancreatic cancer risk. *Cancer Epidemiol. Biomark. Prev.* **2008**, *17*, 2742–2747. [[CrossRef](#)]
28. Chen, K.; Song, L.; Jin, M.J.; Fan, C.H.; Jiang, Q.T.; Yu, W.P. Association between genetic polymorphisms in folate metabolic enzyme genes and colorectal cancer: A nested case-control study. *Zhonghua Zhong Liu Za Zhi* **2006**, *28*, 429–432.
29. Chen, J.; Giovannucci, E.; Hankinson, S.E.; Ma, J.; Willett, W.C.; Spiegelman, D.; Kelsey, K.T.; Hunter, D.J. A prospective study of methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms, and risk of colorectal adenoma. *Carcinogenesis* **1998**, *19*, 2129–2132. [[CrossRef](#)]
30. Ascensão, K.; Szabo, C. Emerging roles of cystathionine  $\beta$ -synthase in various forms of cancer. *Redox Biol.* **2022**, *53*, 102331. [[CrossRef](#)]
31. Ibrahim, H.; Serag, A.; Farag, M.A. Emerging analytical tools for the detection of the third gasotransmitter H<sub>2</sub>S, a comprehensive review. *J. Adv. Res.* **2021**, *27*, 137–153. [[CrossRef](#)]
32. Wang, D.; Yang, H.; Zhang, Y.; Hu, R.; Hu, D.; Wang, Q.; Liu, Y.; Liu, M.; Meng, Z.; Zhou, W.; et al. Inhibition of cystathionine  $\beta$ -synthase promotes apoptosis and reduces cell proliferation in chronic myeloid leukemia. *Signal Transduct. Target. Ther.* **2021**, *6*, 52. [[CrossRef](#)]
33. Stipanuk, M.H.; Ueki, I. Dealing with methionine/homocysteine sulfur: Cysteine metabolism to taurine and inorganic sulfur. *J. Inherit. Metab. Dis.* **2011**, *34*, 17–32. [[CrossRef](#)]
34. Veeranki, S.; Tyagi, S.C. Defective homocysteine metabolism: Potential implications for skeletal muscle malfunction. *Int. J. Mol. Sci.* **2013**, *14*, 15074–15091. [[CrossRef](#)] [[PubMed](#)]
35. Cascella, M.; Arcamone, M.; Morelli, E.; Viscardi, D.; Russo, V.; De Franciscis, S.; Belli, A.; Accardo, R.; Caliendo, D.; De Luca, E.; et al. Erratum to: Multidisciplinary approach and anesthetic management of a surgical cancer patient with methylene tetrahydrofolate reductase deficiency: A case report and review of the literature. *J. Med. Case Rep.* **2015**, *9*, 218. [[CrossRef](#)] [[PubMed](#)]
36. Hankey, G.J.; Eikelboom, J.W. Homocysteine and vascular disease. *Lancet* **1999**, *354*, 407–413. [[CrossRef](#)] [[PubMed](#)]
37. Majumder, A.; Singh, M.; George, A.K.; Homme, R.P.; Laha, A.; Tyagi, S.C. Remote ischemic conditioning as a cytoprotective strategy in vasculopathies during hyperhomocysteinemia: An emerging research perspective. *J. Cell. Biochem.* **2019**, *120*, 77–92. [[CrossRef](#)]
38. Lahiri, K.D.; Datta, H.; Das, H.N. Reference interval determination of total plasma homocysteine in an Indian population. *Indian J. Clin. Biochem.* **2014**, *29*, 74–78. [[CrossRef](#)]
39. Tiahou, G.; Dupuy, A.M.; Jaussent, I.; Sees, D.; Cristol, J.P.; Badiou, S. Determinants of homocysteine levels in Ivorian rural population. *Int. J. Vitam. Nutr. Res.* **2009**, *79*, 319–327. [[CrossRef](#)]
40. Maddocks, O.D.; Labuschagne, C.F.; Adams, P.D.; Vousden, K.H. Serine Metabolism Supports the Methionine Cycle and DNA/RNA Methylation through De Novo ATP Synthesis in Cancer Cells. *Mol. Cell* **2016**, *61*, 210–221. [[CrossRef](#)]
41. Lehotsky, J.; Tothova, B.; Kovalska, M.; Dobrota, D.; Benova, A.; Kalenska, D.; Kaplan, P. Role of Homocysteine in the Ischemic Stroke and Development of Ischemic Tolerance. *Front. Neurosci.* **2016**, *10*, 538. [[CrossRef](#)]
42. Banerjee, I.; Gupta, V.; Ganesh, S. Association of gene polymorphism with genetic susceptibility to stroke in Asian populations: A meta-analysis. *J. Hum. Genet.* **2007**, *52*, 205–219. [[CrossRef](#)] [[PubMed](#)]
43. Gao, S.; Li, H.; Xiao, H.; Yao, G.; Shi, Y.; Wang, Y.; Zhou, X.; Yu, H. Association of MTHFR 677T variant allele with risk of intracerebral haemorrhage: A meta-analysis. *J. Neurol. Sci.* **2012**, *323*, 40–45. [[CrossRef](#)] [[PubMed](#)]
44. Kang, S.; Zhao, X.; Liu, L.; Wu, W.; Zhang, D. Association of the C677T polymorphism in the MTHFR gene with hemorrhagic stroke: A meta-analysis. *Genet. Test. Mol. Biomark.* **2013**, *17*, 412–417. [[CrossRef](#)]
45. Yu, H.H.; Zhang, W.L.; Shi, J.P. Relationship between methylenetetrahydrofolate reductase gene C677T polymorphism and susceptibility of ischemic stroke: A meta-analysis. *Zhonghua Yi Xue Za Zhi* **2011**, *91*, 2060–2064.

46. Sen, U.; Mishra, P.K.; Tyagi, N.; Tyagi, S.C. Homocysteine to hydrogen sulfide or hypertension. *Cell Biochem. Biophys.* **2010**, *57*, 49–58. [[CrossRef](#)] [[PubMed](#)]
47. Diakoumopoulou, E.; Tentolouris, N.; Kirlaki, E.; Perrea, D.; Kitsou, E.; Psallas, M.; Doulgerakis, D.; Katsilambros, N. Plasma homocysteine levels in patients with type 2 diabetes in a Mediterranean population: Relation with nutritional and other factors. *Nutr. Metab. Cardiovasc. Dis.* **2005**, *15*, 109–117. [[CrossRef](#)] [[PubMed](#)]
48. Majumder, A.; Singh, M.; George, A.K.; Behera, J.; Tyagi, N.; Tyagi, S.C. Hydrogen sulfide improves postischemic neoangiogenesis in the hind limb of cystathionine- $\beta$ -synthase mutant mice via PPAR- $\gamma$ /VEGF axis. *Physiol. Rep.* **2018**, *6*, e13858. [[CrossRef](#)]
49. Laha, A.; Majumdar, A.; Singh, M.; Tyagi, S.C. Connecting homocysteine and obesity through pyroptosis, gut microbiome, epigenetics, peroxisome proliferator-activated receptor gamma, and zinc finger protein 407. *Can. J. Physiol. Pharmacol.* **2018**, *96*, 971–976. [[CrossRef](#)]
50. Orendac, M.; Muskova, B.; Richterova, E.; Zvarova, J.; Stefek, M.; Zaykova, E.; Kraus, J.P.; Stribny, J.; Hyaneck, J.; Kozich, V. Is the common 844ins68 polymorphism in the cystathionine beta-synthase gene associated with atherosclerosis? *J. Inherit. Metab. Dis.* **1999**, *22*, 674–675. [[CrossRef](#)]
51. Ding, R.; Lin, S.; Chen, D. The association of cystathionine beta synthase (CBS) T833C polymorphism and the risk of stroke: A meta-analysis. *J. Neurol. Sci.* **2012**, *312*, 26–30. [[CrossRef](#)]
52. de Franchis, R.; Fermo, I.; Mazzola, G.; Sebastio, G.; Di Minno, G.; Coppola, A.; Andria, G.; D'Angelo, A. Contribution of the cystathionine beta-synthase gene (844ins68) polymorphism to the risk of early-onset venous and arterial occlusive disease and of fasting hyperhomocysteinemia. *Thromb. Haemost.* **2000**, *84*, 576–582. [[CrossRef](#)] [[PubMed](#)]
53. McGimpsey, S.J.; Woodside, J.V.; Cardwell, C.; Cahill, M.; Chakravarthy, U. Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism, and risk of retinal vein occlusion: A meta-analysis. *Ophthalmology* **2009**, *116*, 1778–1787. [[CrossRef](#)] [[PubMed](#)]
54. Ray, J.G.; Shmorgun, D.; Chan, W.S. Common C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism: Meta-analysis of 31 studies. *Pathophysiol. Haemost. Thromb.* **2002**, *32*, 51–58. [[CrossRef](#)]
55. Cai, W.; Yin, L.; Yang, F.; Zhang, L.; Cheng, J. Association between Hcy levels and the CBS844ins68 and MTHFR C677T polymorphisms with essential hypertension. *Biomed. Rep.* **2014**, *2*, 861–868. [[CrossRef](#)] [[PubMed](#)]
56. Heifetz, E.M.; Birk, R.Z. MTHFR C677T polymorphism affects normotensive diastolic blood pressure independently of blood lipids. *Am. J. Hypertens.* **2015**, *28*, 387–392. [[CrossRef](#)]
57. Yang, K.M.; Jia, J.; Mao, L.N.; Men, C.; Tang, K.T.; Li, Y.Y.; Ding, H.X.; Zhan, Y.Y. Methylenetetrahydrofolate reductase C677T gene polymorphism and essential hypertension: A meta-analysis of 10,415 subjects. *Biomed. Rep.* **2014**, *2*, 699–708. [[CrossRef](#)]
58. Hua, Y.; Zhao, H.; Kong, Y.; Ye, M. Association between the MTHFR gene and Alzheimer's disease: A meta-analysis. *Int. J. Neurosci.* **2011**, *121*, 462–471. [[CrossRef](#)]
59. Ibrahim, S.; Maqbool, S.; Azam, M.; Iqbal, M.P.; Qamar, R. CBS mutations and MTHFR SNPs causative of hyperhomocysteinemia in Pakistani children. *Mol. Biol. Rep.* **2018**, *45*, 353–360. [[CrossRef](#)]
60. Castro, R.; Rivera, I.; Blom, H.J.; Jakobs, C.; Tavares de Almeida, I. Homocysteine metabolism, hyperhomocysteinemia and vascular disease: An overview. *J. Inherit. Metab. Dis.* **2006**, *29*, 3–20. [[CrossRef](#)]
61. White, R.H. The epidemiology of venous thromboembolism. *Circulation* **2003**, *107*, I4–I8. [[CrossRef](#)] [[PubMed](#)]
62. Liang, R.; Zhou, Y.; Xie, J.; Lv, W.; Kang, B.; Liang, Y.; Chen, Y.; Li, Y. Association of C677T gene polymorphisms of methylenetetrahydrofolate reductase and plasma homocysteine level with hyperlipidemia. *J. South. Med. Univ.* **2014**, *34*, 1195–1198.
63. Al-Rubeaan, K.; Siddiqui, K.; Saeb, A.T.; Nazir, N.; Al-Naqeb, D.; Al-Qasim, S. ACE I/D and MTHFR C677T polymorphisms are significantly associated with type 2 diabetes in Arab ethnicity: A meta-analysis. *Gene* **2013**, *520*, 166–177. [[CrossRef](#)]
64. Chang, W.W.; Zhang, L.; Yao, Y.S.; Su, H.; Jin, Y.L.; Chen, Y. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and susceptibility to diabetic nephropathy in Chinese type 2 diabetic patients: A meta-analysis. *Ren. Fail.* **2013**, *35*, 1038–1043. [[CrossRef](#)] [[PubMed](#)]
65. Yang, S.; Zhang, J.; Feng, C.; Huang, G. MTHFR 677T variant contributes to diabetic nephropathy risk in Caucasian individuals with type 2 diabetes: A meta-analysis. *Metab. Clin. Exp.* **2013**, *62*, 586–594. [[CrossRef](#)] [[PubMed](#)]
66. Zhang, D.; Zhou, Y.; Han, L.; Ji, H.; Li, J. The effect of MTHFR C677T polymorphism on type 2 diabetes mellitus with vascular complications in Chinese Han population: A meta-analysis. *Endocr. J.* **2014**, *61*, 717–726. [[CrossRef](#)]
67. Gouveia, L.O.; Canhao, P. MTHFR and the risk for cerebral venous thrombosis—A meta-analysis. *Thromb. Res.* **2010**, *125*, e153–e158. [[CrossRef](#)]
68. Wu, C.Y.; Yang, M.; Lin, M.; Li, L.P.; Wen, X.Z. MTHFR C677T polymorphism was an ethnicity-dependent risk factor for cervical cancer development: Evidence based on a meta-analysis. *Arch. Gynecol. Obstet.* **2013**, *288*, 595–605. [[CrossRef](#)]
69. Wu, Y.L.; Ding, X.X.; Sun, Y.H.; Yang, H.Y.; Sun, L. Methylenetetrahydrofolate reductase (MTHFR) C677T/A1298C polymorphisms and susceptibility to Parkinson's disease: A meta-analysis. *J. Neurol. Sci.* **2013**, *335*, 14–21. [[CrossRef](#)]
70. Laster, L.; Mudd, S.H.; Finkelstein, J.D.; Irreverre, F. Homocystinuria due to cystathionine synthase deficiency: The metabolism of L-methionine. *J. Clin. Invest.* **1965**, *44*, 1708–1719. [[CrossRef](#)]
71. Finkelstein, J.D.; Martin, J.J. Methionine metabolism in mammals. Distribution of homocysteine between competing pathways. *J. Biol. Chem.* **1984**, *259*, 9508–9513. [[CrossRef](#)] [[PubMed](#)]
72. Finkelstein, J.D.; Kyle, W.E.; Martin, J.L.; Pick, A.M. Activation of cystathionine synthase by adenosylmethionine and adenosylethionine. *Biochem. Biophys. Res. Commun.* **1975**, *66*, 81–87. [[CrossRef](#)] [[PubMed](#)]

73. Stabler, S.P.; Steegborn, C.; Wahl, M.C.; Oliveriusova, J.; Kraus, J.P.; Allen, R.H.; Wagner, C.; Mudd, S.H. Elevated plasma total homocysteine in severe methionine adenosyltransferase I/III deficiency. *Metab. Clin. Exp.* **2002**, *51*, 981–988. [[CrossRef](#)] [[PubMed](#)]
74. Stolzenberg-Solomon, R.Z.; Miller, E.R., 3rd; Maguire, M.G.; Selhub, J.; Appel, L.J. Association of dietary protein intake and coffee consumption with serum homocysteine concentrations in an older population. *Am. J. Clin. Nutr.* **1999**, *69*, 467–475. [[CrossRef](#)] [[PubMed](#)]
75. Selhub, J. Homocysteine metabolism. *Annu. Rev. Nutr.* **1999**, *19*, 217–246. [[CrossRef](#)]
76. Selhub, J.; Jacques, P.F.; Rosenberg, I.H.; Rogers, G.; Bowman, B.A.; Gunter, E.W.; Wright, J.D.; Johnson, C.L. Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991–1994): Population reference ranges and contribution of vitamin status to high serum concentrations. *Ann. Intern. Med.* **1999**, *131*, 331–339. [[CrossRef](#)]
77. Eloranta, T.O.; Martikainen, V.; Smith, T.K. Adaptation of adenosylmethionine metabolism and methionine recycling to variations in dietary methionine in the rat. *Proc. Soc. Exp. Biol. Med.* **1990**, *194*, 364–371. [[CrossRef](#)]
78. Veeranki, S.; Winchester, L.J.; Tyagi, S.C. Hyperhomocysteinemia associated skeletal muscle weakness involves mitochondrial dysfunction and epigenetic modifications. *Biochim. Biophys. Acta* **2015**, *1852*, 732–741. [[CrossRef](#)]
79. Veeranki, S.; Tyagi, S.C. Mechanisms of hyperhomocysteinemia induced skeletal muscle myopathy after ischemia in the CBS-/+ mouse model. *Int. J. Mol. Sci.* **2015**, *16*, 1252–1265. [[CrossRef](#)]
80. Winchester, L.; Veeranki, S.; Givvimani, S.; Tyagi, S.C. Exercise mitigates the adverse effects of hyperhomocysteinemia on macrophages, MMP-9, skeletal muscle, and white adipocytes. *Can. J. Physiol. Pharmacol.* **2014**, *92*, 575–582. [[CrossRef](#)]
81. Ishii, I.; Akahoshi, N.; Yamada, H.; Nakano, S.; Izumi, T.; Suematsu, M. Cystathionine gamma-Lyase-deficient mice require dietary cysteine to protect against acute lethal myopathy and oxidative injury. *J. Biol. Chem.* **2010**, *285*, 26358–26368. [[CrossRef](#)] [[PubMed](#)]
82. Giovannucci, E.; Rimm, E.B.; Ascherio, A.; Stampfer, M.J.; Colditz, G.A.; Willett, W.C. Alcohol, low-methionine-low-folate diets, and risk of colon cancer in men. *J. Natl. Cancer Inst.* **1995**, *87*, 265–273. [[CrossRef](#)] [[PubMed](#)]
83. Ma, J.; Stampfer, M.J.; Christensen, B.; Giovannucci, E.; Hunter, D.J.; Chen, J.; Willett, W.C.; Selhub, J.; Hennekens, C.H.; Gravel, R.; et al. A polymorphism of the methionine synthase gene: Association with plasma folate, vitamin B12, homocyst(e)ine, and colorectal cancer risk. *Cancer Epidemiol. Biomark. Prev.* **1999**, *8*, 825–829.
84. Bravatà, V. Controversial roles of methylenetetrahydrofolate reductase polymorphisms and folate in breast cancer disease. *Int. J. Food Sci. Nutr.* **2015**, *66*, 43–49. [[CrossRef](#)] [[PubMed](#)]
85. Kato, I.; Dnistrian, A.M.; Schwartz, M.; Toniolo, P.; Koenig, K.; Shore, R.E.; Akhmedkhanov, A.; Zeleniuch-Jacquotte, A.; Riboli, E. Serum folate, homocysteine and colorectal cancer risk in women: A nested case-control study. *Br. J. Cancer* **1999**, *79*, 1917–1922. [[CrossRef](#)]
86. de Jong, M.M.; Nolte, I.M.; te Meerman, G.J.; van der Graaf, W.T.; de Vries, E.G.; Sijmons, R.H.; Hofstra, R.M.; Kleibeuker, J.H. Low-penetrance genes and their involvement in colorectal cancer susceptibility. *Cancer Epidemiol. Biomark. Prev.* **2002**, *11*, 1332–1352.
87. Matsuo, K.; Hamajima, N.; Hirai, T.; Kato, T.; Inoue, M.; Takezaki, T.; Tajima, K. Methionine Synthase Reductase Gene A66G Polymorphism is Associated with Risk of Colorectal Cancer. *Asian Pac. J. Cancer Prev.* **2002**, *3*, 353–359.
88. Robien, K.; Ulrich, C.M. 5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: A HuGE minireview. *Am. J. Epidemiol.* **2003**, *157*, 571–582. [[CrossRef](#)]
89. Krajcinovic, M.; Lamothe, S.; Labuda, D.; Lemieux-Blanchard, E.; Theoret, Y.; Moghrabi, A.; Sinnett, D. Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. *Blood* **2004**, *103*, 252–257. [[CrossRef](#)]
90. Singal, R.; Ferdinand, L.; Das, P.M.; Reis, I.M.; Schlesselman, J.J. Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk. *Int. J. Oncol.* **2004**, *25*, 1465–1471. [[CrossRef](#)]
91. Matsuo, K.; Ito, H.; Wakai, K.; Hirose, K.; Saito, T.; Suzuki, T.; Kato, T.; Hirai, T.; Kanemitsu, Y.; Hamajima, H.; et al. One-carbon metabolism related gene polymorphisms interact with alcohol drinking to influence the risk of colorectal cancer in Japan. *Carcinogenesis* **2005**, *26*, 2164–2171. [[CrossRef](#)] [[PubMed](#)]
92. Wu, L.L.; Wu, J.T. Hyperhomocysteinemia is a risk factor for cancer and a new potential tumor marker. *Clin. Chim. Acta* **2002**, *322*, 21–28. [[CrossRef](#)] [[PubMed](#)]
93. Ueland, P.M.; Refsum, H. Plasma homocysteine, a risk factor for vascular disease: Plasma levels in health, disease, and drug therapy. *J. Lab. Clin. Med.* **1989**, *114*, 473–501.
94. Corona, G.; Toffoli, G.; Fabris, M.; Viel, A.; Zarrelli, A.; Donada, C.; Boiocchi, M. Homocysteine accumulation in human ovarian carcinoma ascitic/cystic fluids possibly caused by metabolic alteration of the methionine cycle in ovarian carcinoma cells. *Eur. J. Cancer* **1997**, *33*, 1284–1290. [[CrossRef](#)] [[PubMed](#)]
95. Santotoribio, J.D.; Cañavate-Solano, C.; Garcia-de la Torre, A.; Del Valle-Vazquez, L.; Arce-Matute, F.; Cuadros-Muñoz, J.F.; Sanchez del Pino, M.J.; Bandez-Ruiz, M.J.; Piñuela-Rojas, C.; Perez-Ramos, S. Homocysteine: New tumor marker in pleural fluid. *Tumor Biol.* **2015**, *36*, 7941–7945. [[CrossRef](#)]
96. Shujuan, Y.; Jianxing, Z.; Xin-Yue, C. Methylenetetrahydrofolate reductase genetic polymorphisms and esophageal squamous cell carcinoma susceptibility: A meta-analysis of case-control studies. *Pak. J. Med. Sci.* **2013**, *29*, 693–698. [[PubMed](#)]
97. Marugame, T.; Tsuji, E.; Inoue, H.; Shinomiya, S.; Kiyohara, C.; Onuma, K.; Hamada, H.; Koga, H.; Handa, K.; Hayabuchi, H.; et al. Methylenetetrahydrofolate reductase polymorphism and risk of colorectal adenomas. *Cancer Lett.* **2000**, *151*, 181–186. [[CrossRef](#)]
98. Paynter, R.A.; Hankinson, S.E.; Hunter, D.J.; De Vivo, I. No association between MTHFR 677 C->T or 1298 A->C polymorphisms and endometrial cancer risk. *Cancer Epidemiol. Biomark. Prev.* **2004**, *13*, 1088–1089. [[CrossRef](#)]

99. Safarinejad, M.R.; Shafiei, N.; Safarinejad, S. Relationship between three polymorphisms of methylenetetrahydrofolate reductase (MTHFR C677T, A1298C, and G1793A) gene and risk of prostate cancer: A case-control study. *Prostate* **2010**, *70*, 1645–1657. [[CrossRef](#)]
100. Fang, D.H.; Ji, Q.; Fan, C.H.; An, Q.; Li, J. Methionine synthase reductase A66G polymorphism and leukemia risk: Evidence from published studies. *Leuk. Lymphoma* **2014**, *55*, 1910–1914. [[CrossRef](#)]
101. Wang, P.; Li, S.; Wang, M.; He, J.; Xi, S. Association of MTRR A66G polymorphism with cancer susceptibility: Evidence from 85 studies. *J. Cancer* **2017**, *8*, 266–277. [[CrossRef](#)] [[PubMed](#)]
102. Wu, P.P.; Tang, R.N.; An, L. A meta-analysis of MTRR A66G polymorphism and colorectal cancer susceptibility. *J. BUON* **2015**, *20*, 918–922. [[PubMed](#)]
103. Yoo, J.Y.; Kim, S.Y.; Hwang, J.A.; Hong, S.H.; Shin, A.; Choi, I.J.; Lee, Y.S. Association Study between Folate Pathway Gene Single Nucleotide Polymorphisms and Gastric Cancer in Koreans. *Genom. Inform.* **2012**, *10*, 184–193. [[CrossRef](#)] [[PubMed](#)]
104. Wu, X.; Zou, T.; Cao, N.; Ni, J.; Xu, W.; Zhou, T.; Wang, X. Plasma homocysteine levels and genetic polymorphisms in folate metabolism are associated with breast cancer risk in Chinese women. *Hered. Cancer Clin. Pract.* **2014**, *12*, 2. [[CrossRef](#)]
105. Cui, L.H.; Song, Y.; Si, H.; Shen, F.; Shin, M.H.; Kim, H.N.; Choi, J.S. Folate metabolism-related gene polymorphisms and susceptibility to primary liver cancer in North China. *Med. Oncol.* **2012**, *29*, 1837–1842. [[CrossRef](#)]
106. Tao, M.H.; Shields, P.G.; Nie, J.; Marian, C.; Ambrosone, C.B.; McCann, S.E.; Platek, M.; Krishnan, S.S.; Xie, B.; Edge, S.B.; et al. DNA promoter methylation in breast tumors: No association with genetic polymorphisms in MTHFR and MTR. *Cancer Epidemiol. Biomark. Prev.* **2009**, *18*, 998–1002. [[CrossRef](#)]
107. Semmler, A.; Simon, M.; Moskau, S.; Linnebank, M. The methionine synthase polymorphism c.2756A>G alters susceptibility to glioblastoma multiforme. *Cancer Epidemiol. Biomark. Prev.* **2006**, *15*, 2314–2316. [[CrossRef](#)]
108. Ott, N.; Geddert, H.; Sarbia, M. Polymorphisms in methionine synthase (A2756G) and cystathionine beta-synthase (844ins68) and susceptibility to carcinomas of the upper gastrointestinal tract. *J. Cancer Res. Clin. Oncol.* **2008**, *134*, 405–410. [[CrossRef](#)]
109. Zhao, Y.; Chen, Z.; Ma, Y.; Xia, Q.; Zhang, F.; Fu, D.; Wang, X.F. Lack of association between methionine synthase A2756G polymorphism and digestive system cancer risk: Evidence from 39327 subjects. *PLoS ONE* **2013**, *8*, e61511. [[CrossRef](#)]
110. Wang, L.; Ke, Q.; Chen, W.; Wang, J.; Tan, Y.; Zhou, Y.; Hua, Z.; Ding, W.; Niu, J.; Shen, J.; et al. Polymorphisms of MTHFD1, plasma homocysteine levels, and risk of gastric cancer in a high-risk Chinese population. *Clin. Cancer Res.* **2007**, *13*, 2526–2532. [[CrossRef](#)]
111. Zhang, H.; Ma, H.; Li, L.; Zhang, Z.; Xu, Y. Association of methylenetetrahydrofolate dehydrogenase 1 polymorphisms with cancer: A meta-analysis. *PLoS ONE* **2013**, *8*, e69366. [[CrossRef](#)] [[PubMed](#)]
112. da Silva, L.M.; Galbiatti, A.L.; Ruiz, M.T.; Raposo, L.S.; Maniglia, J.V.; Pavarino, E.C.; Goloni-Bertollo, E.M. MTHFD1 G1958A, BHMT G742A, TC2 C776G and TC2 A67G polymorphisms and head and neck squamous cell carcinoma risk. *Mol. Biol. Rep.* **2012**, *39*, 887–893. [[CrossRef](#)] [[PubMed](#)]
113. Xu, X.; Gammon, M.D.; Zeisel, S.H.; Lee, Y.L.; Wetmur, J.G.; Teitelbaum, S.L.; Bradshaw, P.T.; Neugut, A.I.; Santella, R.M.; Chen, J. Choline metabolism and risk of breast cancer in a population-based study. *FASEB J.* **2008**, *22*, 2045–2052. [[CrossRef](#)] [[PubMed](#)]
114. Mostowska, A.; Myka, M.; Lianeri, M.; Roszak, A.; Jagodziński, P.P. Folate and choline metabolism gene variants and development of uterine cervical carcinoma. *Clin. Biochem.* **2011**, *44*, 596–600. [[CrossRef](#)]
115. Pawlik, P.; Mostowska, A.; Lianeri, M.; Sajdak, S.; Kędzia, H.; Jagodzinski, P.P. Folate and choline metabolism gene variants in relation to ovarian cancer risk in the Polish population. *Mol. Biol. Rep.* **2012**, *39*, 5553–5560. [[CrossRef](#)]
116. Hazra, A.; Wu, K.; Kraft, P.; Fuchs, C.S.; Giovannucci, E.L.; Hunter, D.J. Twenty-four non-synonymous polymorphisms in the one-carbon metabolic pathway and risk of colorectal adenoma in the Nurses' Health Study. *Carcinogenesis* **2007**, *28*, 1510–1519. [[CrossRef](#)]
117. Kurzwelly, D.; Knop, S.; Guenther, M.; Loeffler, J.; Korfel, A.; Thiel, E.; Hebart, H.; Simon, M.; Weller, M.; Linnebank, M.; et al. Genetic variants of folate and methionine metabolism and PCNSL incidence in a German patient population. *J. Neurooncol.* **2010**, *100*, 187–192. [[CrossRef](#)]
118. Gao, C.M.; Takezaki, T.; Wu, J.Z.; Liu, Y.T.; Ding, J.H.; Li, S.P.; Su, P.; Hu, X.; Kai, H.T.; Li, Z.Y.; et al. Polymorphisms in thymidylate synthase and methylenetetrahydrofolate reductase genes and the susceptibility to esophageal and stomach cancer with smoking. *Asian Pac. J. Cancer Prev.* **2004**, *5*, 133–138.
119. Stathopoulou, A.; Vlachonikolis, I.; Mavroudis, D.; Perraki, M.; Kouroussis, C.; Apostolaki, S.; Malamos, N.; Kakolyris, S.; Kotsakis, A.; Xenidis, N.; et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: Evaluation of their prognostic significance. *J. Clin. Oncol.* **2002**, *20*, 3404–3412. [[CrossRef](#)]
120. Refsum, H.; Nurk, E.; Smith, A.D.; Ueland, P.M.; Gjesdal, C.G.; Bjelland, I.; Tverdal, A.; Tell, G.S.; Nygård, O.; Vollset, S.E. The Hordaland Homocysteine Study: A community-based study of homocysteine, its determinants, and associations with disease. *J. Nutr.* **2006**, *136*, 1731s–1740s. [[CrossRef](#)]
121. Gatt, A.; Makris, A.; Cladd, H.; Burcombe, R.J.; Smith, J.M.; Cooper, P.; Thompson, D.; Makris, M. Hyperhomocysteinemia in women with advanced breast cancer. *Int. J. Lab. Hematol.* **2007**, *29*, 421–425. [[CrossRef](#)] [[PubMed](#)]
122. Goyette, P.; Sumner, J.S.; Milos, R.; Duncan, A.M.; Rosenblatt, D.S.; Matthews, R.G.; Rozen, R. Human methylenetetrahydrofolate reductase: Isolation of cDNA, mapping and mutation identification. *Nat. Genet.* **1994**, *7*, 195–200. [[CrossRef](#)]
123. Goyette, P.; Frosst, P.; Rosenblatt, D.S.; Rozen, R. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. *Am. J. Hum. Genet.* **1995**, *56*, 1052–1059. [[PubMed](#)]

124. Kluijtmans, L.A.; Wendel, U.; Stevens, E.M.; van den Heuvel, L.P.; Trijbels, F.J.; Blom, H.J. Identification of four novel mutations in severe methylenetetrahydrofolate reductase deficiency. *Eur. J. Hum. Genet.* **1998**, *6*, 257–265. [[CrossRef](#)]
125. Weisberg, I.; Tran, P.; Christensen, B.; Sibani, S.; Rozen, R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. *Mol. Genet. Metab.* **1998**, *64*, 169–172. [[CrossRef](#)]
126. Sibani, S.; Christensen, B.; O'Ferrall, E.; Saadi, I.; Hiou-Tim, F.; Rosenblatt, D.S.; Rozen, R. Characterization of six novel mutations in the methylenetetrahydrofolate reductase (MTHFR) gene in patients with homocystinuria. *Hum. Mutat.* **2000**, *15*, 280–287. [[CrossRef](#)]
127. Tonetti, C.; Amiel, J.; Munnich, A.; Zittoun, J. Impact of new mutations in the methylenetetrahydrofolate reductase gene assessed on biochemical phenotypes: A familial study. *J. Inherit. Metab. Dis.* **2001**, *24*, 833–842. [[CrossRef](#)]
128. Yano, H.; Nakaso, K.; Yasui, K.; Wakutani, Y.; Nakayasu, H.; Kowa, H.; Adachi, Y.; Nakashima, K. Mutations of the MTHFR gene (428C>T and [458G>T+459C>T]) markedly decrease MTHFR enzyme activity. *Neurogenetics* **2004**, *5*, 135–140. [[CrossRef](#)]
129. Ma, J.; Stampfer, M.J.; Giovannucci, E.; Artigas, C.; Hunter, D.J.; Fuchs, C.; Willett, W.C.; Selhub, J.; Hennekens, C.H.; Rozen, R. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. *Cancer Res.* **1997**, *57*, 1098–1102.
130. Esteller, M.; Garcia, A.; Martinez-Palones, J.M.; Xercavins, J.; Reventos, J. Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility. *Carcinogenesis* **1997**, *18*, 2307–2311. [[CrossRef](#)]
131. Song, C.; Xing, D.; Tan, W.; Wei, Q.; Lin, D. Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population. *Cancer Res.* **2001**, *61*, 3272–3275. [[PubMed](#)]
132. Krajcinovic, M.; Lemieux-Blanchard, E.; Chiasson, S.; Primeau, M.; Costea, I.; Moghrabi, A. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. *Pharmacogenom. J.* **2004**, *4*, 66–72. [[CrossRef](#)] [[PubMed](#)]
133. Zhang, X.D.; Li, Y.T.; Yang, S.Y.; Li, W. Meta-analysis on MTHFR polymorphism and lung cancer susceptibility in East Asian populations. *Biomed. Rep.* **2013**, *1*, 440–446. [[CrossRef](#)] [[PubMed](#)]
134. Dick, D.M. Gene-environment interaction in psychological traits and disorders. *Annu. Rev. Clin. Psychol.* **2011**, *7*, 383–409. [[CrossRef](#)] [[PubMed](#)]
135. Ehrlich, M. DNA hypomethylation in cancer cells. *Epigenomics* **2009**, *1*, 239–259. [[CrossRef](#)]
136. Martin, C.; Zhang, Y. The diverse functions of histone lysine methylation. *Nat. Rev. Mol. Cell Biol.* **2005**, *6*, 838–849. [[CrossRef](#)]
137. Yuan, C.; Zhang, J.; Deng, C.; Xia, Y.; Li, B.; Meng, S.; Jin, X.; Cheng, L.; Li, H.; Zhang, C.; et al. Crosstalk of Histone and RNA Modifications Identified a Stromal-Activated Subtype with Poor Survival and Resistance to Immunotherapy in Gastric Cancer. *Front. Pharmacol.* **2022**, *13*, 868830. [[CrossRef](#)]
138. Handy, D.E.; Castro, R.; Loscalzo, J. Epigenetic modifications: Basic mechanisms and role in cardiovascular disease. *Circulation* **2011**, *123*, 2145–2156. [[CrossRef](#)]
139. Santos-Rebouças, C.B.; Pimentel, M.M. Implication of abnormal epigenetic patterns for human diseases. *Eur. J. Hum. Genet.* **2007**, *15*, 10–17. [[CrossRef](#)]
140. Zhou, S.; Zhang, Z.; Xu, G. Notable epigenetic role of hyperhomocysteinemia in atherogenesis. *Lipids Health Dis.* **2014**, *13*, 134. [[CrossRef](#)]
141. Jiang, L.; Gonda, T.A.; Gamble, M.V.; Salas, M.; Seshan, V.; Tu, S.; Twaddell, W.S.; Hegyi, P.; Lazar, G.; Steele, I.; et al. Global hypomethylation of genomic DNA in cancer-associated myofibroblasts. *Cancer Res.* **2008**, *68*, 9900–9908. [[CrossRef](#)] [[PubMed](#)]
142. Berchuck, J.E.; Baca, S.C.; McClure, H.M.; Korthauer, K.; Tsai, H.K.; Nuzzo, P.V.; Kelleher, K.M.; He, M.; Steinharter, J.A.; Zacharia, S.; et al. Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis. *Clin. Cancer Res.* **2022**, *28*, 928–938. [[CrossRef](#)] [[PubMed](#)]
143. Cahill, N.; Rosenquist, R. Uncovering the DNA methylome in chronic lymphocytic leukemia. *Epigenetics* **2013**, *8*, 138–148. [[CrossRef](#)] [[PubMed](#)]
144. Zhao, P.; Malik, S.; Xing, S. Epigenetic Mechanisms Involved in HCV-Induced Hepatocellular Carcinoma (HCC). *Front. Oncol.* **2021**, *11*, 677926. [[CrossRef](#)] [[PubMed](#)]
145. Ehrlich, M. DNA hypomethylation, cancer, the immunodeficiency, centromeric region instability, facial anomalies syndrome and chromosomal rearrangements. *J. Nutr.* **2002**, *132*, 2424s–2429s. [[CrossRef](#)] [[PubMed](#)]
146. Pappalardo, X.G.; Barra, V. Losing DNA methylation at repetitive elements and breaking bad. *Epigenetics Chromatin* **2021**, *14*, 25. [[CrossRef](#)]
147. Burns, K.H. Transposable elements in cancer. *Nat. Rev. Cancer* **2017**, *17*, 415–424. [[CrossRef](#)]
148. Zhang, N. Role of methionine on epigenetic modification of DNA methylation and gene expression in animals. *Anim. Nutr.* **2018**, *4*, 11–16. [[CrossRef](#)]
149. Lund, G.; Andersson, L.; Lauria, M.; Lindholm, M.; Fraga, M.F.; Villar-Garea, A.; Ballestar, E.; Esteller, M.; Zaina, S. DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E. *J. Biol. Chem.* **2004**, *279*, 29147–29154. [[CrossRef](#)]
150. Devlin, A.M.; Arning, E.; Bottiglieri, T.; Faraci, F.M.; Rozen, R.; Lentz, S.R. Effect of Mthfr genotype on diet-induced hyperhomocysteinemia and vascular function in mice. *Blood* **2004**, *103*, 2624–2629. [[CrossRef](#)]

151. Chaturvedi, P.; Kalani, A.; Givvimani, S.; Kamat, P.K.; Familtseva, A.; Tyagi, S.C. Differential regulation of DNA methylation versus histone acetylation in cardiomyocytes during HHcy in vitro and in vivo: An epigenetic mechanism. *Physiol. Genom.* **2014**, *46*, 245–255. [[CrossRef](#)]
152. Izadi, P.; Noruzinia, M.; Karimipoor, M.; Karbassian, M.H.; Akbari, M.T. Promoter hypermethylation of estrogen receptor alpha gene is correlated to estrogen receptor negativity in Iranian patients with sporadic breast cancer. *Cell J.* **2012**, *14*, 102–109.
153. Zhang, J.G.; Liu, J.X.; Li, Z.H.; Wang, L.Z.; Jiang, Y.D.; Wang, S.R. Dysfunction of endothelial NO system originated from homocysteine-induced aberrant methylation pattern in promoter region of DDAH2 gene. *Chin. Med. J.* **2007**, *120*, 2132–2137. [[CrossRef](#)]
154. Lister, R.; Pelizzola, M.; Dowen, R.H.; Hawkins, R.D.; Hon, G.; Tonti-Filippini, J.; Nery, J.R.; Lee, L.; Ye, Z.; Ngo, Q.M.; et al. Human DNA methylomes at base resolution show widespread epigenomic differences. *Nature* **2009**, *462*, 315–322. [[CrossRef](#)]
155. Mariño-Ramírez, L.; Kann, M.G.; Shoemaker, B.A.; Landsman, D. Histone structure and nucleosome stability. *Expert Rev. Proteom.* **2005**, *2*, 719–729. [[CrossRef](#)] [[PubMed](#)]
156. Millán-Zambrano, G.; Burton, A.; Bannister, A.J.; Schneider, R. Histone post-translational modifications—Cause and consequence of genome function. *Nat. Rev. Genet.* **2022**, *23*, 563–580. [[CrossRef](#)] [[PubMed](#)]
157. Ouyang, Y.; Wu, Q.; Li, J.; Sun, S.; Sun, S. S-adenosylmethionine: A metabolite critical to the regulation of autophagy. *Cell Prolif.* **2020**, *53*, e12891. [[PubMed](#)]
158. Helin, K.; Dhanak, D. Chromatin proteins and modifications as drug targets. *Nature* **2013**, *502*, 480–488. [[CrossRef](#)]
159. Garraway, L.A.; Lander, E.S. Lessons from the cancer genome. *Cell* **2013**, *153*, 17–37. [[CrossRef](#)]
160. Halsall, J.A.; Andrews, S.; Krueger, F.; Rutledge, C.E.; Ficiz, G.; Reik, W.; Turner, B.M. Histone modifications form a cell-type-specific chromosomal bar code that persists through the cell cycle. *Sci. Rep.* **2021**, *11*, 3009. [[CrossRef](#)]
161. Yang, J.X.; Rastetter, R.H.; Wilhelm, D. Non-coding RNAs: An Introduction. *Adv. Exp. Med. Biol.* **2016**, *886*, 13–32. [[CrossRef](#)]
162. Slack, F.J.; Chinnaiyan, A.M. The Role of Non-coding RNAs in Oncology. *Cell* **2019**, *179*, 1033–1055. [[CrossRef](#)]
163. Ratti, M.; Lampis, A.; Ghidini, M.; Salati, M.; Mirchev, M.B.; Valeri, N.; Hahne, J.C. MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside. *Target. Oncol.* **2020**, *15*, 261–278. [[CrossRef](#)] [[PubMed](#)]
164. Volovat, S.R.; Volovat, C.; Hordila, I.; Hordila, D.A.; Mirestean, C.C.; Miron, O.T.; Lungulescu, C.; Scripcariu, D.V.; Stolniceanu, C.R.; Konsoulova-Kirova, A.A.; et al. MiRNA and lncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review. *Front. Oncol.* **2020**, *10*, 526850. [[CrossRef](#)] [[PubMed](#)]
165. Kalani, A.; Kamat, P.K.; Tyagi, S.C.; Tyagi, N. Synergy of homocysteine, microRNA, and epigenetics: A novel therapeutic approach for stroke. *Mol. Neurobiol.* **2013**, *48*, 157–168. [[CrossRef](#)] [[PubMed](#)]
166. George, A.K.; Master, K.; Majumder, A.; Homme, R.P.; Laha, A.; Sandhu, H.S.; Tyagi, S.C.; Singh, M. Circular RNAs constitute an inherent gene regulatory axis in the mammalian eye and brain. *Can. J. Physiol. Pharmacol.* **2019**, *97*, 463–472. [[CrossRef](#)]
167. Singh, M.; George, A.K.; Homme, R.P.; Majumder, A.; Laha, A.; Sandhu, H.S.; Tyagi, S.C. Circular RNAs profiling in the cystathionine- $\beta$ -synthase mutant mouse reveals novel gene targets for hyperhomocysteinemia induced ocular disorders. *Exp. Eye Res.* **2018**, *174*, 80–92. [[CrossRef](#)] [[PubMed](#)]
168. George, A.K.; Homme, R.P.; Majumder, A.; Tyagi, S.C.; Singh, M. Effect of MMP-9 gene knockout on retinal vascular form and function. *Physiol. Genom.* **2019**, *51*, 613–622. [[CrossRef](#)]
169. Homme, R.P.; Singh, M.; Majumder, A.; George, A.K.; Nair, K.; Sandhu, H.S.; Tyagi, N.; Lominadze, D.; Tyagi, S.C. Remodeling of Retinal Architecture in Diabetic Retinopathy: Disruption of Ocular Physiology and Visual Functions by Inflammatory Gene Products and Pyroptosis. *Front. Physiol.* **2018**, *9*, 1268. [[CrossRef](#)]
170. Liu, X.; Tong, Y.; Xia, D.; Peng, E.; Yang, X.; Liu, H.; Ye, T.; Wang, X.; He, Y.; Ye, Z.; et al. Circular RNAs in prostate cancer: Biogenesis, biological functions, and clinical significance. *Mol. Ther.-Nucleic Acids* **2021**, *26*, 1130–1147. [[CrossRef](#)]
171. Singh, M.; George, A.K.; Homme, R.P.; Majumder, A.; Laha, A.; Sandhu, H.S.; Tyagi, S.C. Expression Analysis of the Circular RNA Molecules in the Human Retinal Cells Treated with Homocysteine. *Curr. Eye Res.* **2019**, *44*, 287–293. [[CrossRef](#)] [[PubMed](#)]
172. George, A.K.; Homme, R.P.; Majumder, A.; Laha, A.; Metreveli, N.; Sandhu, H.S.; Tyagi, S.C.; Singh, M. Hydrogen sulfide intervention in cystathionine- $\beta$ -synthase mutant mouse helps restore ocular homeostasis. *Int. J. Ophthalmol.* **2019**, *12*, 754–764. [[CrossRef](#)] [[PubMed](#)]
173. Shackelford, R.E.; Mohammad, I.Z.; Meram, A.T.; Kim, D.; Alotaibi, F.; Patel, S.; Ghali, G.E.; Kevil, C.G. Molecular Functions of Hydrogen Sulfide in Cancer. *Pathophysiology* **2021**, *28*, 437–456. [[CrossRef](#)] [[PubMed](#)]
174. Kimura, H. Hydrogen sulfide as a neuromodulator. *Mol. Neurobiol.* **2002**, *26*, 13–19. [[CrossRef](#)]
175. Guo, H.; Gai, J.W.; Wang, Y.; Jin, H.F.; Du, J.B.; Jin, J. Characterization of hydrogen sulfide and its synthases, cystathionine  $\beta$ -synthase and cystathionine  $\gamma$ -lyase, in human prostatic tissue and cells. *Urology* **2012**, *79*, 483.e1–483.e5. [[CrossRef](#)] [[PubMed](#)]
176. Bhattacharyya, S.; Saha, S.; Giri, K.; Lanza, I.R.; Nair, K.S.; Jennings, N.B.; Rodriguez-Aguayo, C.; Lopez-Berestein, G.; Basal, E.; Weaver, A.L.; et al. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. *PLoS ONE* **2013**, *8*, e79167. [[CrossRef](#)]
177. Arfin, S.; Jha, N.K.; Jha, S.K.; Kesari, K.K.; Ruokolainen, J.; Roychoudhury, S.; Rathi, B.; Kumar, D. Oxidative Stress in Cancer Cell Metabolism. *Antioxidants* **2021**, *10*, 642. [[CrossRef](#)] [[PubMed](#)]
178. Li, S.; Xu, H.X.; Wu, C.T.; Wang, W.Q.; Jin, W.; Gao, H.L.; Li, H.; Zhang, S.R.; Xu, J.Z.; Qi, Z.H.; et al. Angiogenesis in pancreatic cancer: Current research status and clinical implications. *Angiogenesis* **2019**, *22*, 15–36. [[CrossRef](#)]

179. Cai, W.J.; Wang, M.J.; Ju, L.H.; Wang, C.; Zhu, Y.C. Hydrogen sulfide induces human colon cancer cell proliferation: Role of Akt, ERK and p21. *Cell Biol. Int.* **2010**, *34*, 565–572. [[CrossRef](#)]
180. Untereiner, A.A.; Pavlidou, A.; Druzhyna, N.; Papapetropoulos, A.; Hellmich, M.R.; Szabo, C. Drug resistance induces the upregulation of H<sub>2</sub>S-producing enzymes in HCT116 colon cancer cells. *Biochem. Pharmacol.* **2018**, *149*, 174–185. [[CrossRef](#)]
181. Shibuya, N.; Mikami, Y.; Kimura, Y.; Nagahara, N.; Kimura, H. Vascular endothelium expresses 3-mercaptopyruvate sulfurtransferase and produces hydrogen sulfide. *J. Biochem.* **2009**, *146*, 623–626. [[CrossRef](#)]
182. Szabo, C.; Coletta, C.; Chao, C.; Módis, K.; Szczesny, B.; Papapetropoulos, A.; Hellmich, M.R. Tumor-derived hydrogen sulfide, produced by cystathionine- $\beta$ -synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 12474–12479. [[CrossRef](#)] [[PubMed](#)]
183. Sen, S.; Kawahara, B.; Gupta, D.; Tsai, R.; Khachatryan, M.; Roy-Chowdhuri, S.; Bose, S.; Yoon, A.; Faull, K.; Farias-Eisner, R.; et al. Role of cystathionine  $\beta$ -synthase in human breast Cancer. *Free Radic. Biol. Med.* **2015**, *86*, 228–238. [[CrossRef](#)] [[PubMed](#)]
184. Turbat-Herrera, E.A.; Kilpatrick, M.J.; Chen, J.; Meram, A.T.; Cotelingam, J.; Ghali, G.; Kevil, C.G.; Coppola, D.; Shackelford, R.E. Cystathione  $\beta$ -Synthase Is Increased in Thyroid Malignancies. *Anticancer Res.* **2018**, *38*, 6085–6090. [[CrossRef](#)] [[PubMed](#)]
185. Li, D.; Yang, Z.; Liu, Z.; Zou, Q.; Yuan, Y. Clinical Significance of CBS and CCL21 in Gallbladder Adenocarcinomas and Squamous Cell/Adenosquamous Carcinomas. *Appl. Immunohistochem. Mol. Morphol.* **2020**, *28*, 103–110. [[CrossRef](#)]
186. Kim, J.; Hong, S.J.; Park, J.H.; Park, S.Y.; Kim, S.W.; Cho, E.Y.; Do, I.G.; Joh, J.W.; Kim, D.S. Expression of cystathionine beta-synthase is downregulated in hepatocellular carcinoma and associated with poor prognosis. *Oncol. Rep.* **2009**, *21*, 1449–1454. [[CrossRef](#)]
187. Zhao, H.; Li, Q.; Wang, J.; Su, X.; Ng, K.M.; Qiu, T.; Shan, L.; Ling, Y.; Wang, L.; Cai, J.; et al. Frequent epigenetic silencing of the folate-metabolising gene cystathionine-beta-synthase in gastrointestinal cancer. *PLoS ONE* **2012**, *7*, e49683. [[CrossRef](#)]
188. You, J.; Shi, X.; Liang, H.; Ye, J.; Wang, L.; Han, H.; Fang, H.; Kang, W.; Wang, T. Cystathionine- $\gamma$ -lyase promotes process of breast cancer in association with STAT3 signaling pathway. *Oncotarget* **2017**, *8*, 65677–65686. [[CrossRef](#)]
189. Pei, Y.; Wu, B.; Cao, Q.; Wu, L.; Yang, G. Hydrogen sulfide mediates the anti-survival effect of sulforaphane on human prostate cancer cells. *Toxicol. Appl. Pharmacol.* **2011**, *257*, 420–428. [[CrossRef](#)]
190. Zhang, L.; Qi, Q.; Yang, J.; Sun, D.; Li, C.; Xue, Y.; Jiang, Q.; Tian, Y.; Xu, C.; Wang, R. An Anticancer Role of Hydrogen Sulfide in Human Gastric Cancer Cells. *Oxid. Med. Cell. Longev.* **2015**, *2015*, 636410. [[CrossRef](#)]
191. Gai, J.W.; Qin, W.; Liu, M.; Wang, H.F.; Zhang, M.; Li, M.; Zhou, W.H.; Ma, Q.T.; Liu, G.M.; Song, W.H.; et al. Expression profile of hydrogen sulfide and its synthases correlates with tumor stage and grade in urothelial cell carcinoma of bladder. *Urol. Oncol.* **2016**, *34*, 166.e15. [[CrossRef](#)] [[PubMed](#)]
192. Pan, Y.; Ye, S.; Yuan, D.; Zhang, J.; Bai, Y.; Shao, C. Hydrogen sulfide (H<sub>2</sub>S)/cystathionine  $\gamma$ -lyase (CSE) pathway contributes to the proliferation of hepatoma cells. *Mutat. Res.* **2014**, *763–764*, 10–18. [[CrossRef](#)] [[PubMed](#)]
193. Fan, K.; Li, N.; Qi, J.; Yin, P.; Zhao, C.; Wang, L.; Li, Z.; Zha, X. Wnt/ $\beta$ -catenin signaling induces the transcription of cystathionine- $\gamma$ -lyase, a stimulator of tumor in colon cancer. *Cell. Signal.* **2014**, *26*, 2801–2808. [[CrossRef](#)]
194. Breza, J., Jr.; Soltysova, A.; Hudecova, S.; Penesova, A.; Szadvari, I.; Babula, P.; Chovancova, B.; Lencesova, L.; Pos, O.; Breza, J.; et al. Endogenous H<sub>2</sub>S producing enzymes are involved in apoptosis induction in clear cell renal cell carcinoma. *BMC Cancer* **2018**, *18*, 591. [[CrossRef](#)]
195. Wróbel, M.; Czubak, J.; Bronowicka-Adamska, P.; Jurkowska, H.; Adamek, D.; Papla, B. Is development of high-grade gliomas sulfur-dependent? *Molecules* **2014**, *19*, 21350–21362. [[CrossRef](#)]
196. Oláh, G.; Módis, K.; Törő, G.; Hellmich, M.R.; Szczesny, B.; Szabo, C. Role of endogenous and exogenous nitric oxide, carbon monoxide and hydrogen sulfide in HCT116 colon cancer cell proliferation. *Biochem. Pharmacol.* **2018**, *149*, 186–204. [[CrossRef](#)] [[PubMed](#)]
197. Cao, X.; Ding, L.; Xie, Z.Z.; Yang, Y.; Whiteman, M.; Moore, P.K.; Bian, J.S. A Review of Hydrogen Sulfide Synthesis, Metabolism, and Measurement: Is Modulation of Hydrogen Sulfide a Novel Therapeutic for Cancer? *Antioxid. Redox Signal.* **2019**, *31*, 1–38. [[CrossRef](#)]
198. Tu, X.H.; Huang, S.X.; Li, W.S.; Song, J.X. Correlation of methylation of CpG island in cystathionine beta synthase promoter and clinicopathological features in colorectal cancer. *Zhonghua Zhong Liu Za Zhi* **2013**, *35*, 351–355. [[CrossRef](#)]
199. Módis, K.; Coletta, C.; Asimakopoulou, A.; Szczesny, B.; Chao, C.; Papapetropoulos, A.; Hellmich, M.R.; Szabo, C. Effect of S-adenosyl-L-methionine (SAM), an allosteric activator of cystathionine- $\beta$ -synthase (CBS) on colorectal cancer cell proliferation and bioenergetics in vitro. *Nitric Oxide* **2014**, *41*, 146–156. [[CrossRef](#)]
200. Niu, W.; Wang, J.; Qian, J.; Wang, M.; Wu, P.; Chen, F.; Yan, S. Allosteric control of human cystathionine  $\beta$ -synthase activity by a redox active disulfide bond. *J. Biol. Chem.* **2018**, *293*, 2523–2533. [[CrossRef](#)]
201. Takano, N.; Sarfraz, Y.; Gilkes, D.M.; Chaturvedi, P.; Xiang, L.; Suematsu, M.; Zagzag, D.; Semenza, G.L. Decreased expression of cystathionine  $\beta$ -synthase promotes glioma tumorigenesis. *Mol. Cancer Res.* **2014**, *12*, 1398–1406. [[CrossRef](#)]
202. Kimura, Y.; Toyofuku, Y.; Koike, S.; Shibuya, N.; Nagahara, N.; Lefer, D.; Ogasawara, Y.; Kimura, H. Identification of H<sub>2</sub>S<sub>3</sub> and H<sub>2</sub>S produced by 3-mercaptopyruvate sulfurtransferase in the brain. *Sci. Rep.* **2015**, *5*, 14774. [[CrossRef](#)]
203. Mustafa, A.K.; Gadalla, M.M.; Sen, N.; Kim, S.; Mu, W.; Gazi, S.K.; Barrow, R.K.; Yang, G.; Wang, R.; Snyder, S.H. H<sub>2</sub>S signals through protein S-sulphydration. *Sci. Signal.* **2009**, *2*, ra72. [[CrossRef](#)] [[PubMed](#)]



204. d'Emmanuele di Villa Bianca, R.; Mitidieri, E.; Esposito, D.; Donnarumma, E.; Russo, A.; Fusco, F.; Ianaro, A.; Mirone, V.; Cirino, G.; Russo, G.; et al. Human Cystathionine- $\beta$ -Synthase Phosphorylation on Serine227 Modulates Hydrogen Sulfide Production in Human Urothelium. *PLoS ONE* **2015**, *10*, e0136859. [[CrossRef](#)]
205. Sbodio, J.I.; Snyder, S.H.; Paul, B.D. Regulators of the transsulfuration pathway. *Br. J. Pharmacol.* **2019**, *176*, 583–593. [[CrossRef](#)] [[PubMed](#)]
206. Murphy, B.; Bhattacharya, R.; Mukherjee, P. Hydrogen sulfide signaling in mitochondria and disease. *FASEB J.* **2019**, *33*, 13098–13125. [[CrossRef](#)]
207. Hourihan, J.M.; Kenna, J.G.; Hayes, J.D. The gasotransmitter hydrogen sulfide induces nrf2-target genes by inactivating the keep1 ubiquitin ligase substrate adaptor through formation of a disulfide bond between cys-226 and cys-613. *Antioxid. Redox Signal.* **2013**, *19*, 465–481. [[CrossRef](#)]
208. Yang, G.; Pei, Y.; Teng, H.; Cao, Q.; Wang, R. Specificity protein-1 as a critical regulator of human cystathionine gamma-lyase in smooth muscle cells. *J. Biol. Chem.* **2011**, *286*, 26450–26460. [[CrossRef](#)]
209. Sen, N.; Paul, B.D.; Gadalla, M.M.; Mustafa, A.K.; Sen, T.; Xu, R.; Kim, S.; Snyder, S.H. Hydrogen sulfide-linked sulfhydrylation of NF- $\kappa$ B mediates its antiapoptotic actions. *Mol. Cell* **2012**, *45*, 13–24. [[CrossRef](#)]
210. Wang, Y.H.; Huang, J.T.; Chen, W.L.; Wang, R.H.; Kao, M.C.; Pan, Y.R.; Chan, S.H.; Tsai, K.W.; Kung, H.J.; Lin, K.T.; et al. Dysregulation of cystathionine  $\gamma$ -lyase promotes prostate cancer progression and metastasis. *EMBO Rep.* **2019**, *20*, e45986. [[CrossRef](#)]
211. Nagahara, N.; Katayama, A. Post-translational regulation of mercaptopyruvate sulfurtransferase via a low redox potential cysteine-sulfenate in the maintenance of redox homeostasis. *J. Biol. Chem.* **2005**, *280*, 34569–34576. [[CrossRef](#)] [[PubMed](#)]
212. Augsburger, F.; Randi, E.B.; Jendly, M.; Ascencao, K.; Dilek, N.; Szabo, C. Role of 3-Mercaptopyruvate Sulfurtransferase in the Regulation of Proliferation, Migration, and Bioenergetics in Murine Colon Cancer Cells. *Biomolecules* **2020**, *10*, 447. [[CrossRef](#)] [[PubMed](#)]
213. Hayes, J.D.; Dinkova-Kostova, A.T.; Tew, K.D. Oxidative Stress in Cancer. *Cancer Cell* **2020**, *38*, 167–197. [[CrossRef](#)]
214. Whiteman, M.; Armstrong, J.S.; Chu, S.H.; Jia-Ling, S.; Wong, B.S.; Cheung, N.S.; Halliwell, B.; Moore, P.K. The novel neuromodulator hydrogen sulfide: An endogenous peroxynitrite 'scavenger'? *J. Neurochem.* **2004**, *90*, 765–768. [[CrossRef](#)] [[PubMed](#)]
215. Whiteman, M.; Cheung, N.S.; Zhu, Y.Z.; Chu, S.H.; Siau, J.L.; Wong, B.S.; Armstrong, J.S.; Moore, P.K. Hydrogen sulphide: A novel inhibitor of hypochlorous acid-mediated oxidative damage in the brain? *Biochem. Biophys. Res. Commun.* **2005**, *326*, 794–798. [[CrossRef](#)]
216. Yan, S.K.; Chang, T.; Wang, H.; Wu, L.; Wang, R.; Meng, Q.H. Effects of hydrogen sulfide on homocysteine-induced oxidative stress in vascular smooth muscle cells. *Biochem. Biophys. Res. Commun.* **2006**, *351*, 485–491. [[CrossRef](#)]
217. Greiner, R.; Palinkas, Z.; Basell, K.; Becher, D.; Antelmann, H.; Nagy, P.; Dick, T.P. Polysulfides link H<sub>2</sub>S to protein thiol oxidation. *Antioxid. Redox Signal.* **2013**, *19*, 1749–1765. [[CrossRef](#)]
218. Szabo, C. Hydrogen sulphide and its therapeutic potential. *Nat. Rev. Drug Discov.* **2007**, *6*, 917–935. [[CrossRef](#)]
219. Al-Magableh, M.R.; Kemp-Harper, B.K.; Ng, H.H.; Miller, A.A.; Hart, J.L. Hydrogen sulfide protects endothelial nitric oxide function under conditions of acute oxidative stress in vitro. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **2014**, *387*, 67–74. [[CrossRef](#)]
220. Predmore, B.L.; Lefer, D.J.; Gojon, G. Hydrogen sulfide in biochemistry and medicine. *Antioxid. Redox Signal.* **2012**, *17*, 119–140. [[CrossRef](#)]
221. Whiteman, M.; Li, L.; Kostetski, I.; Chu, S.H.; Siau, J.L.; Bhatia, M.; Moore, P.K. Evidence for the formation of a novel nitrosothiol from the gaseous mediators nitric oxide and hydrogen sulphide. *Biochem. Biophys. Res. Commun.* **2006**, *343*, 303–310. [[CrossRef](#)] [[PubMed](#)]
222. Geng, B.; Chang, L.; Pan, C.; Qi, Y.; Zhao, J.; Pang, Y.; Du, J.; Tang, C. Endogenous hydrogen sulfide regulation of myocardial injury induced by isoproterenol. *Biochem. Biophys. Res. Commun.* **2004**, *318*, 756–763. [[CrossRef](#)] [[PubMed](#)]
223. Kimura, Y.; Kimura, H. Hydrogen sulfide protects neurons from oxidative stress. *FASEB J.* **2004**, *18*, 1165–1167. [[CrossRef](#)] [[PubMed](#)]
224. Lu, M.; Hu, L.F.; Hu, G.; Bian, J.S. Hydrogen sulfide protects astrocytes against H<sub>2</sub>O<sub>2</sub>-induced neural injury via enhancing glutamate uptake. *Free Radic. Biol. Med.* **2008**, *45*, 1705–1713. [[CrossRef](#)]
225. Tyagi, N.; Moshal, K.S.; Sen, U.; Vacek, T.P.; Kumar, M.; Hughes, W.M., Jr.; Kundu, S.; Tyagi, S.C. H<sub>2</sub>S protects against methionine-induced oxidative stress in brain endothelial cells. *Antioxid. Redox Signal.* **2009**, *11*, 25–33. [[CrossRef](#)]
226. Kesharwani, V.; Nelson, K.S.; Agrawal, S.K. Effect of sodium hydrosulphide after acute compression injury of spinal cord. *Brain Res.* **2013**, *1527*, 222–229. [[CrossRef](#)]
227. Huang, C.; Kan, J.; Liu, X.; Ma, F.; Tran, B.H.; Zou, Y.; Wang, S.; Zhu, Y.Z. Cardioprotective effects of a novel hydrogen sulfide agent-controlled release formulation of S-propargyl-cysteine on heart failure rats and molecular mechanisms. *PLoS ONE* **2013**, *8*, e69205. [[CrossRef](#)]
228. Wang, C.; Wang, H.Y.; Liu, Z.W.; Fu, Y.; Zhao, B. Effect of endogenous hydrogen sulfide on oxidative stress in oleic acid-induced acute lung injury in rats. *Chin. Med. J.* **2011**, *124*, 3476–3480.
229. Sen, U.; Basu, P.; Abe, O.A.; Givvimani, S.; Tyagi, N.; Metreveli, N.; Shah, K.S.; Passmore, J.C.; Tyagi, S.C. Hydrogen sulfide ameliorates hyperhomocysteinemia-associated chronic renal failure. *Am. J. Physiol. Ren. Physiol.* **2009**, *297*, F410–F419. [[CrossRef](#)]

230. Guo, C.; Liang, F.; Shah Masood, W.; Yan, X. Hydrogen sulfide protected gastric epithelial cell from ischemia/reperfusion injury by Keap1 s-sulfhydration, MAPK dependent anti-apoptosis and NF-kappaB dependent anti-inflammation pathway. *Eur. J. Pharmacol.* **2014**, *725*, 70–78. [[CrossRef](#)]
231. Cui, J.; Liu, L.; Zou, J.; Qiao, W.; Liu, H.; Qi, Y.; Yan, C. Protective effect of endogenous hydrogen sulfide against oxidative stress in gastric ischemia-reperfusion injury. *Exp. Ther. Med.* **2013**, *5*, 689–694. [[CrossRef](#)] [[PubMed](#)]
232. Zhu, X.; Tang, Z.; Cong, B.; Du, J.; Wang, C.; Wang, L.; Ni, X.; Lu, J. Estrogens increase cystathionine-gamma-lyase expression and decrease inflammation and oxidative stress in the myocardium of ovariectomized rats. *Menopause* **2013**, *20*, 1084–1091. [[CrossRef](#)] [[PubMed](#)]
233. Fu, Z.; Liu, X.; Geng, B.; Fang, L.; Tang, C. Hydrogen sulfide protects rat lung from ischemia-reperfusion injury. *Life Sci.* **2008**, *82*, 1196–1202. [[CrossRef](#)]
234. Wen, Y.D.; Wang, H.; Kho, S.H.; Rinkiko, S.; Sheng, X.; Shen, H.M.; Zhu, Y.Z. Hydrogen sulfide protects HUVECs against hydrogen peroxide induced mitochondrial dysfunction and oxidative stress. *PLoS ONE* **2013**, *8*, e53147. [[CrossRef](#)]
235. Liu, Y.Y.; Nagpure, B.V.; Wong, P.T.; Bian, J.S. Hydrogen sulfide protects SH-SY5Y neuronal cells against d-galactose induced cell injury by suppression of advanced glycation end products formation and oxidative stress. *Neurochem. Int.* **2013**, *62*, 603–609. [[CrossRef](#)] [[PubMed](#)]
236. Benetti, L.R.; Campos, D.; Gurgueira, S.A.; Vercesi, A.E.; Guedes, C.E.; Santos, K.L.; Wallace, J.L.; Teixeira, S.A.; Florenzano, J.; Costa, S.K.; et al. Hydrogen sulfide inhibits oxidative stress in lungs from allergic mice in vivo. *Eur. J. Pharmacol.* **2013**, *698*, 463–469. [[CrossRef](#)]
237. Su, Y.W.; Liang, C.; Jin, H.F.; Tang, X.Y.; Han, W.; Chai, L.J.; Zhang, C.Y.; Geng, B.; Tang, C.S.; Du, J.B. Hydrogen sulfide regulates cardiac function and structure in adriamycin-induced cardiomyopathy. *Circ. J.* **2009**, *73*, 741–749. [[CrossRef](#)]
238. Kai, S.; Tanaka, T.; Daijo, H.; Harada, H.; Kishimoto, S.; Suzuki, K.; Takabuchi, S.; Takenaga, K.; Fukuda, K.; Hirota, K. Hydrogen sulfide inhibits hypoxia- but not anoxia-induced hypoxia-inducible factor 1 activation in a von hippel-lindau- and mitochondria-dependent manner. *Antioxid. Redox Signal.* **2012**, *16*, 203–216. [[CrossRef](#)] [[PubMed](#)]
239. Wang, M.; Guo, Z.; Wang, S. Regulation of cystathionine  $\gamma$ -lyase in mammalian cells by hypoxia. *Biochem. Genet.* **2014**, *52*, 29–37. [[CrossRef](#)]
240. Giuffrè, A.; Tomé, C.S.; Fernandes, D.G.F.; Zuhra, K.; Vicente, J.B. Hydrogen Sulfide Metabolism and Signaling in the Tumor Microenvironment. *Adv. Exp. Med. Biol.* **2020**, *1219*, 335–353. [[CrossRef](#)]
241. Zhou, Y.; Li, X.H.; Zhang, C.C.; Wang, M.J.; Xue, W.L.; Wu, D.D.; Ma, F.F.; Li, W.W.; Tao, B.B.; Zhu, Y.C. Hydrogen sulfide promotes angiogenesis by downregulating miR-640 via the VEGFR2/mTOR pathway. *Am. J. Physiol. Cell Physiol.* **2016**, *310*, C305–C317. [[CrossRef](#)] [[PubMed](#)]
242. Wang, M.; Yan, J.; Cao, X.; Hua, P.; Li, Z. Hydrogen sulfide modulates epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via HIF-1 $\alpha$  activation. *Biochem. Pharmacol.* **2020**, *172*, 113775. [[CrossRef](#)] [[PubMed](#)]
243. Szabó, C.; Papapetropoulos, A. Hydrogen sulphide and angiogenesis: Mechanisms and applications. *Br. J. Pharmacol.* **2011**, *164*, 853–865. [[CrossRef](#)] [[PubMed](#)]
244. Wong, R.S. Apoptosis in cancer: From pathogenesis to treatment. *J. Exp. Clin. Cancer Res.* **2011**, *30*, 87. [[CrossRef](#)]
245. Rose, P.; Moore, P.K.; Ming, S.H.; Nam, O.C.; Armstrong, J.S.; Whiteman, M. Hydrogen sulfide protects colon cancer cells from chemopreventative agent beta-phenylethyl isothiocyanate induced apoptosis. *World J. Gastroenterol.* **2005**, *11*, 3990–3997. [[CrossRef](#)] [[PubMed](#)]
246. Zheng, D.; Chen, Z.; Chen, J.; Zhuang, X.; Feng, J.; Li, J. Exogenous hydrogen sulfide exerts proliferation, anti-apoptosis, migration effects and accelerates cell cycle progression in multiple myeloma cells via activating the Akt pathway. *Oncol. Rep.* **2016**, *36*, 1909–1916, Corrigendum in *Oncol. Rep.* **2021**, *45*, 1315. [[CrossRef](#)]
247. Zhen, Y.; Pan, W.; Hu, F.; Wu, H.; Feng, J.; Zhang, Y.; Chen, J. Exogenous hydrogen sulfide exerts proliferation/anti-apoptosis/angiogenesis/migration effects via amplifying the activation of NF- $\kappa$ B pathway in PLC/PRF/5 hepatoma cells. *Int. J. Oncol.* **2015**, *46*, 2194–2204. [[CrossRef](#)]
248. Tiong, C.X.; Lu, M.; Bian, J.S. Protective effect of hydrogen sulphide against 6-OHDA-induced cell injury in SH-SY5Y cells involves PKC/PI3K/Akt pathway. *Br. J. Pharmacol.* **2010**, *161*, 467–480. [[CrossRef](#)]
249. Yang, G.; Zhao, K.; Ju, Y.; Mani, S.; Cao, Q.; Puukila, S.; Khaper, N.; Wu, L.; Wang, R. Hydrogen sulfide protects against cellular senescence via S-sulfhydration of Keap1 and activation of Nrf2. *Antioxid. Redox Signal.* **2013**, *18*, 1906–1919. [[CrossRef](#)]
250. Zhao, K.; Ju, Y.; Li, S.; Altaany, Z.; Wang, R.; Yang, G. S-sulfhydration of MEK1 leads to PARP-1 activation and DNA damage repair. *EMBO Rep.* **2014**, *15*, 792–800. [[CrossRef](#)]
251. Hoesel, B.; Schmid, J.A. The complexity of NF- $\kappa$ B signaling in inflammation and cancer. *Mol. Cancer* **2013**, *12*, 86. [[CrossRef](#)]
252. Rojo de la Vega, M.; Chapman, E.; Zhang, D.D. NRF2 and the Hallmarks of Cancer. *Cancer Cell* **2018**, *34*, 21–43. [[CrossRef](#)] [[PubMed](#)]
253. Lu, Z.; Xu, S. ERK1/2 MAP kinases in cell survival and apoptosis. *IUBMB Life* **2006**, *58*, 621–631. [[CrossRef](#)] [[PubMed](#)]
254. Ray Chaudhuri, A.; Nussenzweig, A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. *Nat. Rev. Mol. Cell Biol.* **2017**, *18*, 610–621. [[CrossRef](#)] [[PubMed](#)]
255. Szczesny, B.; Marcatti, M.; Zatarain, J.R.; Druzhyina, N.; Wiktorowicz, J.E.; Nagy, P.; Hellmich, M.R.; Szabo, C. Inhibition of hydrogen sulfide biosynthesis sensitizes lung adenocarcinoma to chemotherapeutic drugs by inhibiting mitochondrial DNA repair and suppressing cellular bioenergetics. *Sci. Rep.* **2016**, *6*, 36125. [[CrossRef](#)] [[PubMed](#)]

256. Ascenção, K.; Dilek, N.; Augsburg, F.; Panagaki, T.; Zuhra, K.; Szabo, C. Pharmacological induction of mesenchymal-epithelial transition via inhibition of H<sub>2</sub>S biosynthesis and consequent suppression of ACLY activity in colon cancer cells. *Pharmacol. Res.* **2021**, *165*, 105393. [[CrossRef](#)] [[PubMed](#)]
257. Phillips, C.M.; Zatarain, J.R.; Nicholls, M.E.; Porter, C.; Widen, S.G.; Thanki, K.; Johnson, P.; Jawad, M.U.; Moyer, M.P.; Randall, J.W.; et al. Upregulation of Cystathionine- $\beta$ -Synthase in Colonic Epithelia Reprograms Metabolism and Promotes Carcinogenesis. *Cancer Res.* **2017**, *77*, 5741–5754. [[CrossRef](#)]
258. Módis, K.; Ju, Y.; Ahmad, A.; Untereiner, A.A.; Altaany, Z.; Wu, L.; Szabo, C.; Wang, R. S-Sulfhydration of ATP synthase by hydrogen sulfide stimulates mitochondrial bioenergetics. *Pharmacol. Res.* **2016**, *113*, 116–124. [[CrossRef](#)]
259. Folkman, J. Angiogenesis: An organizing principle for drug discovery? *Nat. Rev. Drug Discov.* **2007**, *6*, 273–286. [[CrossRef](#)]
260. Dicks, N.; Gutierrez, K.; Michalak, M.; Bordignon, V.; Agellon, L.B. Endoplasmic reticulum stress, genome damage, and cancer. *Front. Oncol.* **2015**, *5*, 11. [[CrossRef](#)]
261. Wei, H.; Zhang, R.; Jin, H.; Liu, D.; Tang, X.; Tang, C.; Du, J. Hydrogen sulfide attenuates hyperhomocysteinemia-induced cardiomyocyte endoplasmic reticulum stress in rats. *Antioxid. Redox Signal.* **2010**, *12*, 1079–1091. [[CrossRef](#)]
262. Li, C.; Hu, M.; Wang, Y.; Lu, H.; Deng, J.; Yan, X. Hydrogen sulfide preconditioning protects against myocardial ischemia/reperfusion injury in rats through inhibition of endo/sarcoplasmic reticulum stress. *Int. J. Clin. Exp. Pathol.* **2015**, *8*, 7740–7751. [[PubMed](#)]
263. Li, X.; Zhang, K.Y.; Zhang, P.; Chen, L.X.; Wang, L.; Xie, M.; Wang, C.Y.; Tang, X.Q. Hydrogen sulfide inhibits formaldehyde-induced endoplasmic reticulum stress in PC12 cells by upregulation of SIRT-1. *PLoS ONE* **2014**, *9*, e89856. [[CrossRef](#)]
264. Bęłtowski, J. Protein homocysteinylation: A new mechanism of atherogenesis? *Adv. Hyg. Exp. Med.* **2005**, *59*, 392–404.
265. Chen, S.M.; Tang, X.Q. Homocysteinylation and Sulfhydration in Diseases. *Curr. Neuropharmacol.* **2022**, *20*, 1726–1735. [[CrossRef](#)]
266. Majumder, A.; Singh, M.; Tyagi, S.C. Post-menopausal breast cancer: From estrogen to androgen receptor. *Oncotarget* **2017**, *8*, 102739–102758. [[CrossRef](#)] [[PubMed](#)]
267. Majumder, A.; Sandhu, M.; Banerji, D.; Steri, V.; Olshen, A.; Moasser, M.M. The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers. *Sci. Rep.* **2021**, *11*, 9091. [[CrossRef](#)]
268. Gao, X.; Sanderson, S.M.; Dai, Z.; Reid, M.A.; Cooper, D.E.; Lu, M.; Richie, J.P., Jr.; Ciccarella, A.; Calcagnotto, A.; Mikhael, P.G.; et al. Dietary methionine influences therapy in mouse cancer models and alters human metabolism. *Nature* **2019**, *572*, 397–401. [[CrossRef](#)]
269. Mitsuboshi, S.; Niimura, T.; Kanda, M.; Ishida, S.; Zamami, Y.; Ishizawa, K. Risk of Hematologic Events With Coadministration of Methotrexate and the Breast Cancer Resistance Protein Inhibitor Febuxostat. *Ann. Pharmacother.* **2022**, *56*, 910–915. [[CrossRef](#)]
270. Diddens, H.; Niethammer, D.; Jackson, R.C. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate. *Cancer Res.* **1983**, *43*, 5286–5292.
271. Mullarky, E.; Lucki, N.C.; Beheshti Zavareh, R.; Anglin, J.L.; Gomes, A.P.; Nicolay, B.N.; Wong, J.C.; Christen, S.; Takahashi, H.; Singh, P.K.; et al. Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers. *Proc. Natl. Acad. Sci. USA* **2016**, *113*, 1778–1783. [[CrossRef](#)] [[PubMed](#)]
272. Pacold, M.E.; Brimacombe, K.R.; Chan, S.H.; Rohde, J.M.; Lewis, C.A.; Swier, L.J.; Possemato, R.; Chen, W.W.; Sullivan, L.B.; Fiske, B.P.; et al. A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate. *Nat. Chem. Biol.* **2016**, *12*, 452–458. [[CrossRef](#)] [[PubMed](#)]
273. Ducker, G.S.; Chen, L.; Morscher, R.J.; Ghergurovich, J.M.; Esposito, M.; Teng, X.; Kang, Y.; Rabinowitz, J.D. Reversal of Cytosolic One-Carbon Flux Compensates for Loss of the Mitochondrial Folate Pathway. *Cell Metab.* **2016**, *23*, 1140–1153. [[CrossRef](#)] [[PubMed](#)]
274. Hellmich, M.R.; Coletta, C.; Chao, C.; Szabo, C. The therapeutic potential of cystathionine  $\beta$ -synthetase/hydrogen sulfide inhibition in cancer. *Antioxid. Redox Signal.* **2015**, *22*, 424–448. [[CrossRef](#)]
275. Lee, Z.W.; Zhou, J.; Chen, C.S.; Zhao, Y.; Tan, C.H.; Li, L.; Moore, P.K.; Deng, L.W. The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. *PLoS ONE* **2011**, *6*, e21077. [[CrossRef](#)]
276. Lu, S.; Gao, Y.; Huang, X.; Wang, X. GYY4137, a hydrogen sulfide (H<sub>2</sub>S) donor, shows potent anti-hepatocellular carcinoma activity through blocking the STAT3 pathway. *Int. J. Oncol.* **2014**, *44*, 1259–1267. [[CrossRef](#)]
277. Sakuma, S.; Minamino, S.; Takase, M.; Ishiyama, Y.; Hosokura, H.; Kohda, T.; Ikeda, Y.; Fujimoto, Y. Hydrogen sulfide donor GYY4137 suppresses proliferation of human colorectal cancer Caco-2 cells by inducing both cell cycle arrest and cell death. *Heliyon* **2019**, *5*, e02244. [[CrossRef](#)]
278. Tanase, S.; Morino, Y. Irreversible inactivation of aspartate aminotransferases during transamination with L-propargylglycine. *Biochem. Biophys. Res. Commun.* **1976**, *68*, 1301–1308. [[CrossRef](#)]
279. Burnett, G.; Marcotte, P.; Walsh, C. Mechanism-based inactivation of pig heart L-alanine transaminase by L-propargylglycine. Half-site reactivity. *J. Biol. Chem.* **1980**, *255*, 3487–3491. [[CrossRef](#)]
280. Mitra, J.; Bhattacharyya, D. Irreversible inactivation of snake venom l-amino acid oxidase by covalent modification during catalysis of l-propargylglycine. *FEBS Open Bio* **2013**, *3*, 135–143. [[CrossRef](#)]
281. Yadav, P.K.; Yamada, K.; Chiku, T.; Koutmos, M.; Banerjee, R. Structure and kinetic analysis of H<sub>2</sub>S production by human mercaptopyruvate sulfurtransferase. *J. Biol. Chem.* **2013**, *288*, 20002–20013. [[CrossRef](#)]
282. Hanaoka, K.; Sasakura, K.; Suwanai, Y.; Toma-Fukai, S.; Shimamoto, K.; Takano, Y.; Shibuya, N.; Terai, T.; Komatsu, T.; Ueno, T.; et al. Discovery and Mechanistic Characterization of Selective Inhibitors of H<sub>2</sub>S-producing Enzyme: 3-Mercaptopyruvate Sulfurtransferase (3MST) Targeting Active-site Cysteine Persulfide. *Sci. Rep.* **2017**, *7*, 40227. [[CrossRef](#)] [[PubMed](#)]

283. Bantzi, M.; Augsburger, F.; Loup, J.; Berset, Y.; Vasilakaki, S.; Myriantopoulos, V.; Mikros, E.; Szabo, C.; Bochet, C.G. Novel Aryl-Substituted Pyrimidones as Inhibitors of 3-Mercaptopyruvate Sulfurtransferase with Antiproliferative Efficacy in Colon Cancer. *J. Med. Chem.* **2021**, *64*, 6221–6240. [[CrossRef](#)]
284. Zuhra, K.; Augsburger, F.; Majtan, T.; Szabo, C. Cystathionine- $\beta$ -Synthase: Molecular Regulation and Pharmacological Inhibition. *Biomolecules* **2020**, *10*, 697. [[CrossRef](#)] [[PubMed](#)]
285. Asimakopoulou, A.; Panopoulos, P.; Chasapis, C.T.; Coletta, C.; Zhou, Z.; Cirino, G.; Giannis, A.; Szabo, C.; Spyroulias, G.A.; Papapetropoulos, A. Selectivity of commonly used pharmacological inhibitors for cystathionine  $\beta$  synthase (CBS) and cystathionine  $\gamma$  lyase (CSE). *Br. J. Pharmacol.* **2013**, *169*, 922–932. [[CrossRef](#)] [[PubMed](#)]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.